<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000526.pub2" GROUP_ID="INFECTN" ID="306899103014382222" MERGED_FROM="" MODIFIED="2017-09-10 11:09:06 +0100" MODIFIED_BY="Deirdre Walshe" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.2">
<COVER_SHEET MODIFIED="2017-09-10 11:06:36 +0100" MODIFIED_BY="Deirdre Walshe">
<TITLE MODIFIED="2017-05-18 12:55:56 +0100" MODIFIED_BY="[Empty name]">Interventions for treating tuberculous pericarditis</TITLE>
<CONTACT>
<PERSON ID="13900" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Bongani</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Mayosi</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bongani.mayosi@uct.ac.za</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>University of Cape Town</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 21 4066200</PHONE_1>
<PHONE_2/>
<FAX_1>+27 21 4486815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2017-09-10 11:06:36 +0100" MODIFIED_BY="Deirdre Walshe">
<PERSON ID="14134" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Charles</FIRST_NAME>
<MIDDLE_INITIALS>S</MIDDLE_INITIALS>
<LAST_NAME>Wiysonge</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>wiysonge@yahoo.com</EMAIL_1>
<EMAIL_2>charles.wiysonge@mrc.ac.za</EMAIL_2>
<URL>http://www.mrc.ac.za/cochrane/cochrane.htm</URL>
<MOBILE_PHONE>+27 - 71 852 3010</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Cochrane South Africa</DEPARTMENT>
<ORGANISATION>South African Medical Research Council</ORGANISATION>
<ADDRESS_1>Francie van Zijl Drive, Parow Valley</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP>7505</ZIP>
<REGION>Western Cape</REGION>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 71 852 3010</PHONE_1>
<PHONE_2>+27 21 938 0438</PHONE_2>
<FAX_1>+27 21 938 0836</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="0AB8855A82E26AA2004A583DA8213DBF" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Mpiko</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ntsekhe</LAST_NAME>
<SUFFIX/>
<POSITION>Head of Division</POSITION>
<EMAIL_1>mpiko.ntsekhe@uct.ac.za</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Cardiology</DEPARTMENT>
<ORGANISATION>Groote Schuur Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2>Observatory 7925</ADDRESS_2>
<CITY>Cape Town</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 (21) 404-6084</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="30B07AAB82E26AA2001AB0E368175469" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Lehana</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Thabane</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>thabanl@mcmaster.ca</EMAIL_1>
<EMAIL_2>http://www.thecem.net/biostat_intro.php</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1>50 Charlton Ave E</ADDRESS_1>
<ADDRESS_2>Room H325, St. Joseph's Healthcare</ADDRESS_2>
<CITY>Hamilton</CITY>
<ZIP>L8N 4A6</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 905 522 1155 Ext: 33720</PHONE_1>
<PHONE_2/>
<FAX_1>+1 905 308 7212</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6985" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Jimmy</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Volmink</LAST_NAME>
<SUFFIX/>
<POSITION>Dean</POSITION>
<EMAIL_1>jvolmink@sun.ac.za</EMAIL_1>
<EMAIL_2/>
<URL>www.sun.ac.za</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences</DEPARTMENT>
<ORGANISATION>Stellenbosch University</ORGANISATION>
<ADDRESS_1>PO Box 241</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP>8000</ZIP>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 21 938 9200</PHONE_1>
<PHONE_2/>
<FAX_1>+27 21 931 8100</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1508241325236409918725515163424" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Dumisani</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Majombozi</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>eldumasto@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>0769350153</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences</DEPARTMENT>
<ORGANISATION>Stellenbosch University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1508241322550088924479173965978" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Freedom</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gumedze</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>freedom.gumedze@uct.ac.za</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Statistical Sciences</DEPARTMENT>
<ORGANISATION>University of Cape Town</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1409221131511460318201223913858" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Shaheen</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pandie</LAST_NAME>
<SUFFIX/>
<POSITION>Interventional Cardiologist</POSITION>
<EMAIL_1>pandieshaheen@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>0823199030</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>University of Cape Town</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27823199030</PHONE_1>
<PHONE_2>+214046544</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13900" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Bongani</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Mayosi</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bongani.mayosi@uct.ac.za</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>University of Cape Town</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1>+27 21 4066200</PHONE_1>
<PHONE_2/>
<FAX_1>+27 21 4486815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2017-09-10 11:06:36 +0100" MODIFIED_BY="Deirdre Walshe">
<UP_TO_DATE>
<DATE DAY="27" MONTH="3" YEAR="2017"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="27" MONTH="3" YEAR="2017"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="27" MONTH="3" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-09-08 09:56:51 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2017-09-08 09:55:21 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="9" YEAR="2017"/>
<DESCRIPTION>
<P>We updated this review, added new authors, and included new trials. The conclusion of this review changed compared to the previous published version.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-09-08 09:56:51 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="9" YEAR="2017"/>
<DESCRIPTION>
<P>The author team updated this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-05-10 14:37:47 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-05-10 14:37:47 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format with minor editing.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-12 19:04:21 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="1" YEAR="2005"/>
<DESCRIPTION>
<P>New studies found but not yet included or excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-12 19:04:33 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="5" YEAR="2003"/>
<DESCRIPTION>
<P>Minor update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-11-11 12:49:43 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="6" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment. Issue 4, 2002: Hakim 2000 added.</P>
<P>New studies found and included or excluded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2017-06-25 20:49:34 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2017-06-25 20:49:27 +0100" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Cardiac Clinic Research Fund, University of Cape Town</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2015-04-30 22:48:39 +0100" MODIFIED_BY="[Empty name]">
<NAME>Stellenbosch University</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2015-04-30 22:49:22 +0100" MODIFIED_BY="[Empty name]">
<NAME>South African Medical Research Council</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2017-06-25 20:49:27 +0100" MODIFIED_BY="[Empty name]">
<NAME>Liverpool School of Tropical Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2017-06-25 20:49:34 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2017-06-25 20:49:34 +0100" MODIFIED_BY="[Empty name]">
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Grant: 5242</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-08-02 15:52:00 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2017-08-02 15:52:00 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-05-05 22:16:57 +0100" MODIFIED_BY="[Empty name]">Treatment for tuberculosis infection of the membrane around the heart</TITLE>
<SUMMARY_BODY MODIFIED="2017-08-02 15:52:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>What is the issue?</B>
</P>
<P>Tuberculosis infection of the pericardium surrounding the heart is uncommon but life-threatening.</P>
<P>
<B>What is the aim of this review?</B>
</P>
<P>The aim of this Cochrane Review was to assess the effects of treatments for people with tuberculous pericarditis.</P>
<P>
<B>What is this important?</B>
</P>
<P>Doctors prescribe antituberculous drugs for six months, drain fluid from the pericardium if the patient has heart failure, and sometimes remove the pericardium if it is thick and making the patient ill and sometimes give corticosteroids to reduce the effects of the inflammation.</P>
<P>
<B>What are the main results of the review?</B>
</P>
<P>Cochrane researchers collected and examined all potentially relevant studies and found seven trials, all conducted in sub-Saharan Africa. Six trials evaluated corticosteroids. Other treatments evaluated included <I>Mycobacterium indicus pranii </I>immunotherapy, colchicine, and surgical removal of fluid under general anaesthesia. This review is a new edition of the 2002 review.</P>
<P>In people not infected with HIV, six trials found that additional steroids may reduce deaths overall (<I>low certainty evidence</I>) and probably reduce deaths caused by pericarditis (<I>moderate certainty evidence</I>). Steroids may prevent reaccumulation of fluid in the pericardial space (<I>low certainty evidence</I>). However, we do not know whether or not corticosteroids have an effect on constriction or cancer among HIV-negative people (<I>very low certainty evidence</I>).</P>
<P>In people living with HIV, most people evaluated in the included trials were not on antiretroviral drugs. For these patients, corticosteroids may reduce constrictive pericarditis (<I>low certainty evidence</I>), but we do not know if this translates into a reduction in the number of deaths or cancer (<I>very low certainty evidence</I>). Corticosteroids may have little or no effect on reaccumulation of fluid in the pericardial space (<I>low certainty evidence</I>).</P>
<P>Colchicine was evaluated in one trial of 33 people, with insufficient data to make any conclusions about an effect.</P>
<P>Based on one trial, it is uncertain whether adding <I>M. indicus pranii</I> immunotherapy to antituberculous drugs has an effect on any outcome in people with tuberculous pericarditis regardless of their HIV status (<I>very low certainty evidence</I>).</P>
<P>Open surgical drainage of the fluid accumulating between the heart and the membrane using general anaesthesia may be associated with less life-threatening reaccumulation of fluid in people who are not infected with HIV, but conclusions are not possible as the number of participants studied was too small. We did not find an eligible trial that assessed the effects of open surgical drainage in people living with HIV.</P>
<P>The review authors found no eligible trials that examined the length of antituberculous treatment needed nor the effects of other adjunctive treatments for tuberculous pericarditis.</P>
<P>
<B>How up-to-date is this review?</B>
</P>
<P>The review authors searched for trials published up to 27 March 2017.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-08-02 15:51:25 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2017-07-31 12:25:16 +0100" MODIFIED_BY="[Empty name]">
<P>Tuberculous pericarditis can impair the heart's function and cause death; long term, it can cause the membrane to fibrose and constrict causing heart failure. In addition to antituberculous chemotherapy, treatments include corticosteroids, drainage, and surgery.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-07-31 01:05:42 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of treatments for tuberculous pericarditis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-07-31 00:41:35 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Infectious Diseases Group Specialized Register (27 March 2017); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (2017, Issue 2); MEDLINE (1966 to 27 March 2017); Embase (1974 to 27 March 2017); and LILACS (1982 to 27 March 2017). In addition we searched the metaRegister of Controlled Trials (mRCT) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal using 'tuberculosis' and 'pericard*' as search terms on 27 March 2017. We searched ClinicalTrials.gov and contacted researchers in the field of tuberculous pericarditis. This is a new version of the original 2002 review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-06-22 19:43:49 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomized controlled trials (RCTs) and quasi-RCTs.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-07-31 01:05:42 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently screened search outputs, evaluated study eligibility, assessed risk of bias, and extracted data; and we resolved any discrepancies by discussion and consensus. One trial assessed the effects of both corticosteroid and <I>Mycobacterium indicus pranii</I> treatment in a two-by-two factorial design<I>;</I> we excluded data from the group that received both interventions. We conducted fixed-effect meta-analysis and assessed the certainty of the evidence using the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-08-02 15:51:25 +0100" MODIFIED_BY="[Empty name]">
<P>Seven trials met the inclusion criteria; all were from sub-Saharan Africa and included 1959 participants, with 1051/1959 (54%) HIV-positive. All trials evaluated corticosteroids and one each evaluated colchicine, <I>M. indicus pranii </I>immunotherapy, and open surgical drainage. Four trials (1841 participants) were at low risk of bias, and three trials (118 participants) were at high risk of bias.</P>
<P>In people who are not infected with HIV, corticosteroids may reduce deaths from all causes (risk ratio (RR) 0.80, 95% confidence interval (CI) 0.59 to 1.09; 660 participants, 4 trials, <I>low certainty evidence</I>) and the need for repeat pericardiocentesis (RR 0.85, 95% CI 0.70 to 1.04; 492 participants, 2 trials, <I>low certainty evidence</I>). Corticosteroids probably reduce deaths from pericarditis (RR 0.39, 95% CI 0.19 to 0.80; 660 participants, 4 trials, <I>moderate certainty evidence</I>). However, we do not know whether or not corticosteroids have an effect on constriction or cancer among HIV-negative people (<I>very low certainty evidence</I>).</P>
<P>In people living with HIV, only 19.9% (203/1959) were on antiretroviral drugs. Corticosteroids may reduce constriction (RR 0.55, 0.26 to 1.16; 575 participants, 3 trials, <I>low certainty evidence</I>). It is uncertain whether corticosteroids have an effect on all-cause death or cancer (<I>very low certainty evidence</I>); and may have little or no effect on repeat pericardiocentesis (RR 1.02, 0.89 to 1.18; 517 participants, 2 trials, <I>low certainty evidence</I>).</P>
<P>For colchicine among people living with HIV, we found one small trial (33 participants) which had insufficient data to make any conclusions about any effects on death or constrictive pericarditis.</P>
<P>Irrespective of HIV status, due to very low certainty evidence from one trial, it is uncertain whether adding <I>M. indicus pranii</I> immunotherapy to antituberculous drugs has an effect on any outcome.</P>
<P>Open surgical drainage for effusion may reduce repeat pericardiocentesis In HIV-negative people (RR 0.23, 95% CI 0.07 to 0.76; 122 participants, 1 trial, <I>low certainty evidence</I>) but may make little or no difference to other outcomes. We did not find an eligible trial that assessed the effects of open surgical drainage in people living with HIV.</P>
<P>The review authors found no eligible trials that examined the length of antituberculous treatment needed nor the effects of other adjunctive treatments for tuberculous pericarditis.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-08-01 20:55:10 +0100" MODIFIED_BY="[Empty name]">
<P>For HIV-negative patients, corticosteroids may reduce death. For HIV-positive patients not on antiretroviral drugs, corticosteroids may reduce constriction. For HIV-positive patients with good antiretroviral drug viral suppression, clinicians may consider the results from HIV-negative patients more relevant.</P>
<P>Further research may help evaluate percutaneous drainage of the pericardium under local anaesthesia, the timing of pericardiectomy in tuberculous constrictive pericarditis, and new antibiotic regimens.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-07-31 01:45:58 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2017-07-05 14:46:26 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2017-07-05 14:40:58 +0100" MODIFIED_BY="[Empty name]">
<P>Tuberculous pericarditis refers to an infection of the membrane that covers the heart (pericardium) by the bacterium <I>Mycobacterium tuberculosis.</I> Infection of the pericardium can result in fluid accumulation around the heart, which constrains the heart's pumping action (tamponade), and is life-threatening. Sometimes the infection causes a thickening of the pericardium without an effusion (constrictive pericarditis), and this can also constrain the pumping action (<LINK REF="REF-Mayosi-2005" TYPE="REFERENCE">Mayosi 2005</LINK>; <LINK REF="REF-Ntsekhe-2012" TYPE="REFERENCE">Ntsekhe 2012</LINK>). Tuberculous pericarditis manifests with fatigue, shortness of breath, swelling of the body, and can cause death.</P>
<P>Healthcare practitioners in low- and middle-income countries, where tuberculosis is common, are familiar with the condition (<LINK REF="REF-Gelfand-1957" TYPE="REFERENCE">Gelfand 1957</LINK>; <LINK REF="REF-Strang-1984" TYPE="REFERENCE">Strang 1984</LINK>). In high-income countries, the condition occurs in less than 5% of all people with tuberculosis (<LINK REF="REF-Lorell-1997" TYPE="REFERENCE">Lorell 1997</LINK>; <LINK REF="REF-Imazio-2015" TYPE="REFERENCE">Imazio 2015</LINK>). The human immunodeficiency virus (HIV) epidemic has resulted in more cases of tuberculosis in Africa and other resource-constrained regions, with a consequent rise in tuberculous pericarditis (<LINK REF="REF-Cegielski-1990" TYPE="REFERENCE">Cegielski 1990</LINK>; <LINK REF="REF-Mayosi-2006" TYPE="REFERENCE">Mayosi 2006</LINK>; <LINK REF="REF-Mayosi-2008" TYPE="REFERENCE">Mayosi 2008</LINK>). Post-mortem examinations conducted before the HIV era indicate that the pericardium is involved in 1% of people infected with tuberculosis (<LINK REF="REF-Fowler-1991" TYPE="REFERENCE">Fowler 1991</LINK>). However, identical studies in people who died with advanced HIV reveal that extrapulmonary disease with multiple organ involvement is more frequent (<LINK REF="REF-Lucas-1993" TYPE="REFERENCE">Lucas 1993</LINK>; <LINK REF="REF-Rana-1997" TYPE="REFERENCE">Rana 1997</LINK>). In people living with HIV who have pericardial effusion, tuberculosis is the cause in over four-fifths of cases (<LINK REF="REF-Ntsekhe-2005" TYPE="REFERENCE">Ntsekhe 2005</LINK>). In addition, the burden of tuberculous pericarditis experienced a rapid increase in regions of the world where tuberculosis-HIV co-infection is common (<LINK REF="REF-Ntsekhe-2013" TYPE="REFERENCE">Ntsekhe 2013</LINK>). This could be explained in part by the fact that the lifetime risk of tuberculosis in immune-competent people without HIV infection is 10% (<LINK REF="REF-Lawn-2011" TYPE="REFERENCE">Lawn 2011</LINK>), which increases to a yearly risk of 10% early in HIV infection and up to a 30% yearly risk in people with advanced immunosuppression (<LINK REF="REF-Maartens-2007" TYPE="REFERENCE">Maartens 2007</LINK>).</P>
<P>In the pre-antibiotic era, mortality of people with tuberculous pericarditis was 80% to 90% (<LINK REF="REF-Harvey-1937" TYPE="REFERENCE">Harvey 1937</LINK>), but the advent of effective antituberculous chemotherapy in the 1940s resulted in a decrease in case fatality rate to about 35% by 1970 (<LINK REF="REF-Rooney-1970" TYPE="REFERENCE">Rooney 1970</LINK>). However, even with antituberculous drug regimens that contain rifampicin and isoniazid, the mortality rate remains high and is estimated to be between 8% and 17% in people without HIV infection (<LINK REF="REF-Desai-1979" TYPE="REFERENCE">Desai 1979</LINK>; <LINK REF="REF-Bhan-1980" TYPE="REFERENCE">Bhan 1980</LINK>). In addition, HIV infection has an adverse effect on mortality rate (<LINK REF="REF-Mayosi-2005" TYPE="REFERENCE">Mayosi 2005</LINK>; <LINK REF="REF-Ntsekhe-2008" TYPE="REFERENCE">Ntsekhe 2008</LINK>; <LINK REF="STD-Wiysonge-2008" TYPE="STUDY">Wiysonge 2008</LINK>). In one study, 185 participants with tuberculous pericarditis were consecutively enrolled in 15 referral hospitals in three African countries (Cameroon, Nigeria, and South Africa) between March 2004 and October 2004; and followed up during the six-month course of antituberculous treatment (<LINK REF="REF-Mayosi-2006" TYPE="REFERENCE">Mayosi 2006</LINK>). The mortality rate in this study was 17% in people without clinical evidence of HIV infection and 40% in people with clinical features of HIV infection (<LINK REF="REF-Mayosi-2008" TYPE="REFERENCE">Mayosi 2008</LINK>). HIV-associated tuberculous pericarditis more often occurs as part of a disseminated process with a greater amount of heart muscle involvement, and patients have larger fluid accumulation in the pericardium (<LINK REF="REF-Ntsekhe-2013" TYPE="REFERENCE">Ntsekhe 2013</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2017-06-23 19:52:48 +0100" MODIFIED_BY="[Empty name]">
<P>Doctors currently prescribe rifampicin, isoniazid, pyrazinamide, and ethambutol for six months; remove fluid from the pericardium if the patient is very sick; and remove the membrane if it is thick and making the patient ill (<LINK REF="REF-Mayosi-2002" TYPE="REFERENCE">Mayosi 2002</LINK>). However, the number of complications and deaths due to the disease remain high (<LINK REF="REF-Mayosi-2008" TYPE="REFERENCE">Mayosi 2008</LINK>; <LINK REF="REF-Ntsekhe-2013" TYPE="REFERENCE">Ntsekhe 2013</LINK>). It has been proposed that adding corticosteroids to antituberculous antibiotics would lead to further decreases in the aggressiveness of the disease and deaths. Some study authors recommend the routine use of corticosteroids in all cases of tuberculous pericarditis (<LINK REF="REF-Alzeer-1993" TYPE="REFERENCE">Alzeer 1993</LINK>; <LINK REF="REF-Senderovitz-1994" TYPE="REFERENCE">Senderovitz 1994</LINK>; <LINK REF="REF-Strang-1997" TYPE="REFERENCE">Strang 1997</LINK>). In contrast, other experts advise that corticosteroids should be reserved for people who are critically ill with recurrent large effusion and who do not respond to pericardial drainage and antituberculous drugs alone (<LINK REF="REF-Lorell-1997" TYPE="REFERENCE">Lorell 1997</LINK>).</P>
<P>In addition to the corticosteroid controversy, there is no consensus regarding the optimal use of other therapeutic interventions (<LINK REF="REF-Ntsekhe-2013" TYPE="REFERENCE">Ntsekhe 2013</LINK>). Removal of fluid can be percutaneous under local anaesthesia or surgical under general anaesthesia. Furthermore, doctors can differ in the way they manage this condition in terms of duration of antituberculous drugs and when to operate. Other potential treatments for tuberculous pericarditis may include intrapericardial fibrinolysis (<LINK REF="REF-Augustin-2011" TYPE="REFERENCE">Augustin 2011</LINK>), cellular therapy, use of repurposed drugs, cytokine therapy (<LINK REF="REF-Zumla-2015" TYPE="REFERENCE">Zumla 2015</LINK>), and surgical removal of the thickened membrane (that is pericardiectomy) (<LINK REF="REF-Schrire-1967" TYPE="REFERENCE">Schrire 1967</LINK>; <LINK REF="REF-Quayle-1987" TYPE="REFERENCE">Quayle 1987</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2017-06-25 18:56:29 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Length of treatment</HEADING>
<P>Various specialists recommend different antibiotic treatment regimens of different lengths, from six months to 12 months (<LINK REF="REF-Sagrist_x00e0__x002d_Sauleda-1988" TYPE="REFERENCE">Sagristà-Sauleda 1988</LINK>; <LINK REF="REF-Fowler-1991" TYPE="REFERENCE">Fowler 1991</LINK>; <LINK REF="REF-Koh-1994" TYPE="REFERENCE">Koh 1994</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>). It is uncertain whether longer treatment leads to better outcomes (<LINK REF="REF-Mayosi-2002" TYPE="REFERENCE">Mayosi 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Corticosteroids</HEADING>
<P>The inflammatory response to tuberculous bacilli penetrating the pericardium is responsible for the morbidity and mortality associated with tuberculous pericarditis (<LINK REF="REF-Mayosi-2005" TYPE="REFERENCE">Mayosi 2005</LINK>). Corticosteroids are anti-inflammatory drugs that may attenuate the inflammatory response and improve outcomes by reducing the accumulation of fluid or development of adhesions in the pericardium (<LINK REF="STD-Wiysonge-2008" TYPE="STUDY">Wiysonge 2008</LINK>). In people living with HIV, active tuberculosis increases immune activation and accelerates progression to the acquired immunodeficiency syndrome; which results in early death. Corticosteroids may improve survival in HIV-positive people that have tuberculous pericarditis by modulating this immunological response (<LINK REF="STD-Wiysonge-2008" TYPE="STUDY">Wiysonge 2008</LINK>). However, there is concern that corticosteroids may increase the risk of opportunistic infections and cancer in people living with HIV (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Immunomodulators</HEADING>
<P>As a result of advancements in the understanding of the immunopathogenesis of tuberculosis, there has been an increasing interest in immunotherapies as adjunctive treatments to standard antituberculous drug regimens. <I>Mycobacterium indicus pranii</I> is a non-pathogenic, saprophytic, rapidly growing atypical <I>Mycobacterium</I> species that has immunomodulating properties (<LINK REF="REF-Saini-2009" TYPE="REFERENCE">Saini 2009</LINK>). When administered as an intradermal heat-killed vaccine, <I>M. indicus pranii</I> stimulates a Th1 cellular immune response against shared epitopes for <I>M. tuberculosis</I>, which leads to an improved cell-mediated immune response, and therefore less severe disease (<LINK REF="REF-Ganju-1990" TYPE="REFERENCE">Ganju 1990</LINK>; <LINK REF="REF-Singh-1992" TYPE="REFERENCE">Singh 1992</LINK>). A systematic review suggested that <I>M. indicus pranii</I> administration may reduce the time to cure of pulmonary tuberculosis, while acknowledging the need for further large trials (<LINK REF="REF-Pandie-2014" TYPE="REFERENCE">Pandie 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Surgical options</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Early drainage</HEADING>
<P>Complete drainage of the pericardial fluid is sometimes performed as an open surgical procedure under general anaesthesia (<LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>), or percutaneously under local anaesthesia with ultrasound or fluoroscopic guidance. The requirement and optimal method for drainage is not known (<LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Removal of the pericardium</HEADING>
<P>In tuberculous constrictive pericarditis, some specialists advise an early conservative approach with surgery applied to patients who do not respond after an initial period of antituberculous medication (<LINK REF="REF-Schrire-1967" TYPE="REFERENCE">Schrire 1967</LINK>). Others advise early surgery in all affected cases (<LINK REF="REF-Quayle-1987" TYPE="REFERENCE">Quayle 1987</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</THEORY>
<IMPORTANCE MODIFIED="2017-07-05 14:46:26 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane Review first published in 2000 (<LINK REF="REF-Mayosi-2000" TYPE="REFERENCE">Mayosi 2000</LINK>), and previously updated in 2002 (<LINK REF="REF-Mayosi-2002" TYPE="REFERENCE">Mayosi 2002</LINK>). The previous version included four trials of corticosteroids (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>). Early publications of small trials conducted in the pre-HIV era reported fewer deaths with corticosteroids compared to placebo, but the confidence interval (CI) ranged from a substantial reduction to a clinically important increase in deaths (risk ratio 0.65, 95% CI 0.36 to 1.16; 350 participants, 2 trials) (<LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>). Similar results were obtained among people living with HIV (risk ratio 0.50, 95% CI 0.19 to 1.28; 58 participants, 1 trial) (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>). One trial showed that complete drainage of the pericardial fluid may relieve cardiac tamponade (<LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>). However, two previously included trials have reported additional data (<LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>), and various potentially eligible trials have been published since 2002 (<LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Cui-2005" TYPE="STUDY">Cui 2005</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>; <LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-06-25 20:28:54 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of treatments for tuberculous pericarditis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-07-05 15:02:53 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2017-06-25 20:33:51 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2017-06-25 20:33:38 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) and quasi-RCTs.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-06-25 20:33:38 +0100" MODIFIED_BY="[Empty name]">
<P>People of all ages that required treatment for clinically diagnosed tuberculous pericarditis (effusive, constrictive, or effusive-constrictive), whether HIV-negative or HIV-positive.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-06-25 20:33:38 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Long versus shorter durations of antituberculous chemotherapy.</LI>
<LI>Corticosteroids versus no corticosteroids.</LI>
<LI>Immunomodulators versus no immunomodulators.</LI>
<LI>Surgical procedures versus conservative management.</LI>
<LI>Other treatments for tuberculous pericarditis.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-06-25 20:33:51 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-06-25 20:33:51 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Deaths from all causes.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-06-25 20:33:51 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Death from pericarditis.</LI>
<LI>Constrictive pericarditis.</LI>
<LI>Repeat pericardiocentesis.</LI>
<LI>Cancer.</LI>
<LI>Hospitalization.</LI>
<LI>Pericardiectomy.</LI>
<LI>Opportunistic infections.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-07-05 14:47:40 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2017-06-25 20:34:36 +0100" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).</P>
<P>We searched the following databases using the strategy described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>: the Cochrane Infectious Diseases Group Specialized Register (27 March 2017); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (2017, Issue 2); MEDLINE (1966 to 27 March 2017); Embase (1974 to 27 March 2017); and LILACS (1982 to 27 March 2017).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-07-05 14:47:40 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the metaRegister of Controlled Trials (mRCT) and the WHO International Clinical Trials Registry Platform (ICTRP) search portal using 'tuberculosis' and 'pericard*' as search terms on 27 March 2017.</P>
<P>We also searched ClinicalTrials.gov and contacted researchers in the field of tuberculous pericarditis in March 2017.</P>
<P>In addition, we examined existing reviews of tuberculous pericarditis for relevant citations (<LINK REF="REF-Schrire-1967" TYPE="REFERENCE">Schrire 1967</LINK>; <LINK REF="REF-Bhan-1980" TYPE="REFERENCE">Bhan 1980</LINK>; <LINK REF="REF-Fowler-1991" TYPE="REFERENCE">Fowler 1991</LINK>; <LINK REF="REF-Fowler-1992" TYPE="REFERENCE">Fowler 1992</LINK>; <LINK REF="REF-Alzeer-1993" TYPE="REFERENCE">Alzeer 1993</LINK>; <LINK REF="REF-Senderovitz-1994" TYPE="REFERENCE">Senderovitz 1994</LINK>; <LINK REF="REF-Fowler-1995" TYPE="REFERENCE">Fowler 1995</LINK>; <LINK REF="REF-Cisneros-1996" TYPE="REFERENCE">Cisneros 1996</LINK>; <LINK REF="REF-Dooley-1997" TYPE="REFERENCE">Dooley 1997</LINK>; <LINK REF="REF-Strang-1997" TYPE="REFERENCE">Strang 1997</LINK>; <LINK REF="REF-Mayosi-2002" TYPE="REFERENCE">Mayosi 2002</LINK>; <LINK REF="REF-Ntsekhe-2003" TYPE="REFERENCE">Ntsekhe 2003</LINK>; <LINK REF="REF-Mayosi-2005" TYPE="REFERENCE">Mayosi 2005</LINK>; <LINK REF="REF-Syed-2007" TYPE="REFERENCE">Syed 2007</LINK>; <LINK REF="REF-Imazio-2015" TYPE="REFERENCE">Imazio 2015</LINK>; <LINK REF="REF-Zumla-2015" TYPE="REFERENCE">Zumla 2015</LINK>).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-07-05 15:02:53 +0100" MODIFIED_BY="[Empty name]">
<P>We conducted screening of search outputs, assessment of potentially eligible studies, assessment of risk of bias, and data extraction for this review in line with the Cochrane policy on trial authors who are also review authors (<LINK REF="REF-Kliner-2014" TYPE="REFERENCE">Kliner 2014</LINK>). In addition, two Cochrane Infectious Disease Group (CIDG) Editors (Paul Garner and David Sinclair) provided oversight for data collection and analysis.</P>
<STUDY_SELECTION MODIFIED="2017-06-25 20:40:32 +0100" MODIFIED_BY="[Empty name]">
<P>Three review authors, Charles Wiysonge (CSW), Dumo Majombozi (DM), and Bongani M Mayosi (BMM), independently screened abstracts identified by the search strategy for potentially eligible studies. The three review authors obtained the full-text articles of any potentially relevant articles and then assessed these studies using the prespecified trial inclusion criteria, respecting the Cochrane policy on trial authors who are also review authors (<LINK REF="REF-Kliner-2014" TYPE="REFERENCE">Kliner 2014</LINK>). We resolved any disagreements by discussion and consensus.</P>
<P>Six review authors, Mpiko Ntsekhe (MN), Lehana Thabane (LT), Jimmy Volmink (JV), Freedom Gumedze (FG), Shaheen Pandie (SP), and BMM, were involved in one trial that met the inclusion criteria of this review (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). Two review authors who were not involved with this trial, namely CSW and DM, independently performed the application of the inclusion criteria, 'Risk of bias' assessments, and data extraction for this trial. We excluded one potentially eligible study that did not meet the inclusion criteria and documented the reason for exclusion in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table. Four review authors, CSW, MN, FG, JV, and BMM, are the authors of an excluded study (<LINK REF="STD-Wiysonge-2008" TYPE="STUDY">Wiysonge 2008</LINK>). In order to conform to existing Cochrane policies (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>; <LINK REF="REF-Kliner-2014" TYPE="REFERENCE">Kliner 2014</LINK>), a review author who was not involved in this study (DM) made the initial assessment of the eligibility of this study. We have included a study that is awaiting assessment in the '<LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>' table (<LINK REF="STD-Cui-2005" TYPE="STUDY">Cui 2005</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-06-25 20:42:54 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (either CSW and BMM, or CSW and DM) independently extracted information from the included trials on methods used, participant characteristics, interventions, and outcomes. For all outcomes, we extracted the number of participants randomized and the number of participants analysed. The trials identified and included in this review all randomized individual participants and reported dichotomous outcomes. For each trial, we extracted the number of participants randomized to each intervention, as well as the number of participants with an outcome of interest and the number included in the analysis by the trial authors.</P>
<P>The published article from the <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK> trial did not provide data by HIV status, but we requested and obtained these data from the study statistician (FG). CSW entered the data into Review Manager (RevMan) (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), and the study statistician FG verified the entered data for accuracy.</P>
<P>Multiple publications from the same data constituted one included trial, and we marked the publication that provided the most data to the analyses as the primary reference (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). If data were available on prespecified outcomes at two or more periods, we took the more complete or later one into account (<LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-06-25 20:43:47 +0100" MODIFIED_BY="[Empty name]">
<P>One review author (CSW) assessed the risk of bias in each included trial using Cochrane's 'Risk of bias' assessment tool for assessing the risk of bias in intervention studies (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), and two review authors (BMM and DM) verified this assessment; in line with the Cochrane policy on trial authors who are also review authors (<LINK REF="REF-Kliner-2014" TYPE="REFERENCE">Kliner 2014</LINK>). We assessed whether adequate steps were taken to reduce the risk of bias across seven specific domains, namely, random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; completeness of outcome data; selective outcome reporting; and other issues. For each included trial, we described what the trial authors reported that they did for each domain and decided the risk of bias for that domain by assigning a judgement of 'low', 'high', or 'unclear risk' of bias.</P>
<P>We categorized each included study into one of two levels of bias: low or high risk of bias. Studies with a high risk of selection bias (from inadequate random sequence generation and/or allocation concealment), detection bias (from lack of blinding of outcome assessment), or attrition bias (from incomplete outcome data) were categorized as having high risk of bias. We considered all other included trials to have a low risk of bias. We compared the results of independent 'Risk of bias' assessments and resolved disagreements by consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-07-05 15:01:32 +0100" MODIFIED_BY="[Empty name]">
<P>All of the included trials reported dichotomous data, so we expressed the results as risk ratios (RR) with 95% CIs for each outcome.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2017-06-25 20:44:25 +0100" MODIFIED_BY="[Empty name]">
<P>We did not encounter any unit of analysis issues in this review, as all included trials were individually RCTs.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-06-25 20:44:25 +0100" MODIFIED_BY="[Empty name]">
<P>We stratified analyses by HIV status. However, data on HIV status were unavailable in three trials that were conducted (or started recruitment) in South Africa before the onset of the HIV epidemic in the country. We have assumed that the participants in these studies did not have HIV infection (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>). One trial only enrolled HIV-positive people (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>), and two recruited both HIV-positive and HIV-negative people (<LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). The published paper from one of the two trials did not disaggregate results by HIV status (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). We requested and obtained the disaggregated outcome data from the trial statistician (FG).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-06-25 20:44:36 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed whether there was heterogeneity of study participants, interventions, and outcomes in order to make a qualitative assessment of the extent to which the included studies were similar to each other. We then included clinically homogeneous studies in meta-analyses and assessed heterogeneity of study results by visually inspecting the forest plots to check for overlapping CIs. In addition, we assessed heterogeneity of effects using the Chi² test of homogeneity; with statistical significance defined at the 10% alpha level (that is, P = 0.10). We also used the I² statistic to quantify the proportion of observed variation of effects across studies, which reflected variation in true effect sizes rather than sampling error (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-05-20 19:16:32 +0100" MODIFIED_BY="[Empty name]">
<P>There were too few included studies to examine publication bias using a funnel plot (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-07-05 15:02:53 +0100" MODIFIED_BY="[Empty name]">
<P>Using both unpublished (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>), and published data (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>), we analysed trial participants in groups to which they were randomized; regardless of how much of the intended intervention they actually received. One included study used a 2 x 2 factorial design, in which participants received prednisolone plus <I>M. indicus pranii</I>, prednisolone plus placebo, <I>M. indicus pranii</I> plus placebo, or double placebo. There was a suggestion of clinical interaction between prednisolone and <I>M. indicus pranii</I> on cancer incidence (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). Ten of the 14 cases of cancer (71.4%) occurred in the group that took prednisolone plus <I>M. indicus pranii. </I>Therefore, in the analysis of intervention effects, we considered data from the group that took only one active intervention (that is, prednisolone or <I>M. indicus pranii</I>, as the case may be); and excluded data from the group that received both interventions.</P>
<P>We used meta-analysis with a fixed-effect model to calculate the summary statistics. We stratified analyses according to HIV status and the type of treatment and control intervention, for example, adjunctive corticosteroids versus placebo or no treatment in HIV-negative people, adjunctive corticosteroids versus placebo or no treatment in people living with HIV.</P>
<P>In addition, we used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to assess the certainty of the evidence for each outcome (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>). We have summarized the certainty of the evidence for corticosteroids in the 'Summary of findings' tables (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>), which we constructed using GRADEpro Guideline Development Tool software (<LINK REF="REF-GRADEpro-GDT-2014" TYPE="REFERENCE">GRADEpro GDT 2014</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-06-25 20:45:15 +0100" MODIFIED_BY="[Empty name]">
<P>We only conducted meta-analyses for studies with homogeneous participants, interventions, and outcomes. If we had at least 10 studies in any meta-analysis that showed significant statistical heterogeneity (that is, P &lt; 0.10), we would have explored possible sources of heterogeneity by performing subgroup analyses; with subgroups defined by clinical syndromes of tuberculous pericarditis (that is, pericardial effusion versus constriction) and risk of bias (that is, low versus high).</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-07-07 16:05:26 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2017-07-07 16:05:26 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2017-07-07 16:05:26 +0100" MODIFIED_BY="[Empty name]">
<P>We have presented a PRISMA diagram that illustrates the study selection process in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>For this Cochrane Review update, we performed a literature search up to 27 March 2017 covering all years; including the years covered by the previous version of the review (<LINK REF="REF-Mayosi-2002" TYPE="REFERENCE">Mayosi 2002</LINK>). This literature search yielded 17 publications. We judged four of the publications to be clearly irrelevant to the review and excluded them. We obtained the full-text articles of the 13 potentially eligible publications and assessed them for eligibility. Four articles, which contain data from four distinct studies (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>), were already included in the previous published version of the review (<LINK REF="REF-Mayosi-2002" TYPE="REFERENCE">Mayosi 2002</LINK>). We excluded one article due to ineligible study design (<LINK REF="STD-Wiysonge-2008" TYPE="STUDY">Wiysonge 2008</LINK>), and another one is awaiting assessment (<LINK REF="STD-Cui-2005" TYPE="STUDY">Cui 2005</LINK>). One study has not yet published outcome data and we classified it as ongoing (<LINK REF="STD-NCT02673879" TYPE="STUDY">NCT02673879</LINK>). The remaining six publications, which contain data from six distinct studies, met our inclusion criteria (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>; <LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>). The most recent follow-up data for two included trials were published as one article (<LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-06-25 20:52:16 +0100" MODIFIED_BY="[Empty name]">
<P>The seven eligible trials consisted of six single-country studies conducted in South Africa (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>) and Zimbabwe (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>), as well as a multicountry study conducted in Kenya, Malawi, Mozambique, Nigeria, Sierra Leone, South Africa, Uganda, and Zimbabwe (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). The interventions evaluated were as follows.</P>
<UL>
<LI>Corticosteroids (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>).</LI>
<LI>Colchicine (<LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>).</LI>
<LI>
<I>M. indicus pranii </I>immunotherapy (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>).</LI>
<LI>Open surgical drainage on admission in participants with tuberculous pericardial effusion (<LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>).</LI>
</UL>
<P>We have provided details of the included studies in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables.</P>
<SUBSECTION>
<HEADING LEVEL="4">Optimum duration of treatment</HEADING>
<P>We did not find any eligible studies that assessed different durations of antituberculosis drug regimens .</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Corticosteroids</HEADING>
<P>We have provided key characteristics of the six included corticosteroid trials in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>The six trials enrolled a total of 1926 participants. Over half of the participants (1018/1926; 52.9%) were confirmed HIV-positive. Only one study gave antiretroviral drugs to participants, with 203 (22%) of these HIV-positive participants on antiretroviral drugs, and thus overall only 19.9% of participants in the meta-analysis on antiretroviral therapy at enrolment. Five trials enrolled people with pericardial effusion (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>), and one enrolled those with pericardial constriction (<LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>).</P>
<P>The corticosteroids assessed were cortisone (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>), prednisone and triamcinolone hexacetonide (<LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>), and prednisolone (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). <LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK> did not specify the length of follow-up and <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK> reported it as one year; <LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK> as 18 months; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK> as two years; and <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK> and <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK> as 10 years.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Colchicine</HEADING>
<P>One trial tested the effects of colchicine among 33 people with a definite or probable diagnosis of tuberculous pericarditis in Kimberley, South Africa (<LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>). All 33 participants were HIV-positive and had pericardial effusion at enrolment. Participants in the intervention arm received colchicine 1.0 mg per day for six weeks. The control arm received identical placebo for six weeks as well. The length of follow-up was 16 weeks (<LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">
<I>M. indicus pranii </I>immunotherapy</HEADING>
<P>One trial evaluated the effects of an immunomodulator, <I>M. indicus pranii,</I> among 1250 people aged 18 years or older in sub-Saharan Africa (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). Two thirds (840/1250; 67.2%) of the participants were confirmed to be HIV-positive; with 172 (20.5%) on antiretroviral therapy at enrolment. All participants had pericardial effusion at enrolment. The <I>M. indicus pranii</I> preparation was given in five doses; at the time of enrolment and at 2 weeks, 4 weeks, 6 weeks, and 3 months. The control arm received identical placebo following the same schedule, and the length of follow-up was two years. This trial also assessed the effects of corticosteroids (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Surgical drainage</HEADING>
<P>One trial assessed the effects of routine open surgical drainage on admission compared to no open surgical drainage in 122 participants with tuberculous pericardial effusion in Umtata, South Africa (<LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>). This trial was conducted before the onset of the HIV epidemic in the country. This study reported data at two years and at 10 years of follow-up. This trial also assessed the effects of corticosteroids (<LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intrapericardial fibrinolysis</HEADING>
<P>We found an ongoing trial that is assessing the effects of complete percutaneous pericardial drainage using intrapericardial alteplase compared to conventional pericardiocentesis in Cape Town, South Africa. The study started in 2016 and plans to recruit 2176 people with large pericardial effusion due to tuberculous and non-tuberculous pericarditis. The trial started with a pilot phase involving 218 people. This will confirm the feasibility of conducting a large-scale multicentre clinical trial of intrapericardial fibrinolysis in people with large pericardial effusions (<LINK REF="STD-NCT02673879" TYPE="STUDY">NCT02673879</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other treatments</HEADING>
<P>We did not find eligible studies that assessed other potential treatments for tuberculous pericarditis such as pericardiectomy, percutaneous drainage of the pericardium under local anaesthesia, cellular therapy, use of repurposed drugs, or cytokine therapy.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-06-25 21:06:55 +0100" MODIFIED_BY="[Empty name]">
<P>The excluded study is a cross-sectional analysis of the contemporary use of adjunctive corticosteroids in the management of patients with tuberculous pericarditis in Africa (<LINK REF="STD-Wiysonge-2008" TYPE="STUDY">Wiysonge 2008</LINK>). Despite being observational in nature, this study is indexed in electronic databases as a controlled trial. We have provided furthermore details on this study in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table.</P>
<SUBSECTION>
<HEADING LEVEL="3">Studies awaiting assessment</HEADING>
<P>One study is awaiting assessment, because the full-text article is in Chinese and we do not yet have an English translation (<LINK REF="STD-Cui-2005" TYPE="STUDY">Cui 2005</LINK>). In the study, consecutively recruited participants were "randomly" assigned to intervention or control arms, but the study authors did not provide any details about random sequence generation and allocation concealment in the study abstract. We have provided available details on this study in the '<LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>' table.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-07-06 09:57:54 +0100" MODIFIED_BY="[Empty name]">
<P>We have summarized our 'Risk of bias' judgements for each included trial in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2017-06-25 20:52:28 +0100" MODIFIED_BY="[Empty name]">
<P>Five trials adequately generated the randomization sequence by either a computer (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>; <LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>), or a random number list (<LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>). The adequacy of the generation of the randomization sequence was unclear in one trial (<LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>), and inadequate in the other trial (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>). The concealment of allocation to treatment arms was adequate in five trials (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>; <LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>), and inadequate in two trials (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2017-06-25 20:52:28 +0100" MODIFIED_BY="[Empty name]">
<P>Participants, care providers, and outcome assessors were blinded to treatment allocation in four trials (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). One study did not use blinding (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>). One study reported that "upon completion of the research period, the blinding was unveiled", but does not provide details on how the blinding was done (<LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>). In the sixth study there was blinding of participants and care providers, but it is unclear if outcome assessors were blind to treatment allocation (<LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-06-25 20:52:28 +0100" MODIFIED_BY="[Empty name]">
<P>Loss to follow-up was minimal (0% to 5%) and non-differential in four included trials (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). One trial did not adequately report losses to follow-up (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>), but losses to follow-up were high (15% to 16%) in two trials (<LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-06-25 20:52:40 +0100" MODIFIED_BY="[Empty name]">
<P>One trial was free of reporting bias as the planned outcomes (as indicated in the prospective trial registration [ClinicalTrials.gov registration; NCT100810849] and published protocol) were reported in the trial report (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). It was unclear to us if the remaining six studies (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>) were free from reporting bias; since none of the study protocols were available and none of the trials were prospectively registered.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-06-25 20:52:40 +0100" MODIFIED_BY="[Empty name]">
<P>There is no evidence that the included studies had a high risk of other sources of bias; apart from those described above.</P>
<SUBSECTION>
<HEADING LEVEL="3">Overall 'Risk of bias' assessment</HEADING>
<P>Based on the results of the 'Risk of bias' assessments for the seven domains above, we classified each included trial as either at low risk of bias or high risk of bias. Four trials had a low risk of bias (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). The other three included trials were each at high risk of bias (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>).</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-07-05 15:22:42 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Corticosteroids versus no corticosteroids in HIV-negative people</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1. Deaths from all causes</HEADING>
<P>Four trials showed that corticosteroids may reduce deaths from all causes in HIV-negative people (<LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>), but the 95% CI includes the possibility of both a large beneficial effect and a small increase in harm: risk ratio (RR) 0.80, 95% CI 0.59 to 1.09; 660 participants, 4 trials; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). We rated the certainty of the evidence as low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2. Deaths from pericarditis</HEADING>
<P>Four trials provided data on deaths from pericarditis in people without HIV infection (<LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). Pooling these data shows that corticosteroids probably reduce deaths from pericarditis: RR 0.39, 95% CI 0.19 to 0.80; 660 participants, 4 trials; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>. We rated the certainty of the evidence as moderate (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3. Constrictive pericarditis</HEADING>
<P>Based on two included trials, <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK> and <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>, we are uncertain whether corticosteroids reduce the risk of constrictive pericarditis in people without HIV infection: RR 0.72, 95% CI 0.34 to 1.55; 281 participants, 2 trials; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). This evidence is of very low certainty (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4. Repeat pericardiocentesis</HEADING>
<P>Based on two included trials, <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK> and <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>, corticosteroids may reduce the reaccumulation of fluid requiring repeat drainage of the pericardium among HIV-negative people, but the CIs include the possibility of both large beneficial effects and a small increase in harm: RR 0.85, 95% CI 0.70 to 1.04; 492 participants, 2 trials; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>. We rated the certainty of the evidence as low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5. Cancer</HEADING>
<P>From the limited data on cancer reported by one trial (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>), we are uncertain about the effect of corticosteroids on the risk of cancer (RR 0.85, 95% CI 0.05 to 13.80; 256 participants (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) in HIV-negative people, as the evidence is of very low certainty (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6. Hospitalization</HEADING>
<P>Only one trial reported on this outcome (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). We are uncertain whether corticosteroids reduce the risk of hospitalization in HIV-negative people (RR 0.98, 95% CI 0.57 to 1.70; 256 participants, 1 trial; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), as the currently available evidence is of very low certainty. We downgraded the evidence by two for imprecision, as the CI ranges from clinically important benefits to a large increase in harm. In addition, we downgraded by one for selective reporting, given that data were only reported by one of four trials that recruited HIV-negative people.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.7. Pericardiectomy</HEADING>
<P>Based on data from four trials (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>), we are uncertain about the effects of corticosteroids on the risk of pericardiectomy in HIV-negative people: RR 0.91, 95% CI 0.58 to 1.41; 432 participants, 4 trials; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). We rated the evidence to be of very low certainty. We downgraded the evidence by two for imprecision, as the CI ranges from large benefits to clinically important harms. We further downgraded by one for study limitations, given that two of the four trials were at high risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.8. Opportunistic infections</HEADING>
<P>We do not know whether corticosteroids have an effect on opportunistic infections as the certainty of the evidence was assessed as very low (RR 1.71, 95% CI 0.44 to 6.69; 256 participants, 1 trial; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). We downgraded the evidence by two for imprecision, as the CI ranges from clinically important benefits to a large increase in harm. In addition, we downgraded by one for selective reporting, given that data were only reported by one of four trials that recruited HIV-negative people.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Corticosteroids versus no corticosteroids in people living with HIV infection</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2.1. Deaths from all causes</HEADING>
<P>Three included trials reported on this outcome (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). It is uncertain whether corticosteroids have an effect on the risk of deaths from any cause among people living with HIV (RR 0.91, 95% CI 0.34 to 2.42; 575 participants, 3 trials; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). This evidence is of very low certainty (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2. Deaths from pericarditis</HEADING>
<P>Two trials provided data on the effects of corticosteroids on deaths from pericarditis among 517 people living with HIV (<LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). From these data, we are uncertain whether corticosteroids have an effect on the risk of deaths from pericarditis in HIV-positive people (RR 1.07, 95% CI 0.46 to 2.54; 517 participants, 2 trials; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>; <I>very low certainty evidence</I>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3. Constrictive pericarditis</HEADING>
<P>Currently available data from three included trials (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>), show that corticosteroids may reduce the risk of constrictive pericarditis among people living with HIV, but the CIs include the possibility of both large beneficial effects and a small increase in harm (RR 0.55, 0.26 to 1.16; 575 participants, 3 trials; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <I>low certainty evidence</I>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4. Repeat pericardiocentesis</HEADING>
<P>Two trials reported data on the risk of reaccumulation of fluids requiring repeat drainage of the pericardium in HIV-positive people (<LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). The combined data show that corticosteroids may have little or no effect on this outcome (RR 1.02, 95% CI 0.89 to 1.18; 517 participants, 2 trials; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; <I>low certainty evidence</I>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5. Cancer</HEADING>
<P>Based on currently available data from one included trial, <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>, we are uncertain about the effects of corticosteroids on the risk of cancer in people living with HIV (RR 1.62, 95% CI 0.27 to 9.77; 502 participants, 1 trial; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>; <I>very low certainty evidence</I>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6. Hospitalization</HEADING>
<P>Based on one included trial, <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>, corticosteroids may reduce the risk of hospitalization in people living with HIV, but the CIs include the possibility of both large beneficial effects and a small increase in harm (RR 0.80, 95% CI 0.59 to 1.09; 502 participants, 1 trial; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). This evidence is of low certainty. We downgraded the evidence by one for imprecision, as the CI ranges from clinically important benefits to little or no effect. In addition, we downgraded by one for selective reporting, given that data were only reported by one of three trials that recruited HIV-negative people.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7. Pericardiectomy</HEADING>
<P>There is insufficient evidence from one included trial, <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>, to determine whether corticosteroids have an effect on the risk of pericardiectomy in people living with HIV (RR 2.10, 95% CI 0.10 to 44.40; 15 participants, 1 trial; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>; <I>very low certainty evidence</I>). We downgraded the evidence by two for imprecision, as the CI ranges from substantial benefits to clinically important harms. We further downgraded by one for selective reporting, given that data were only reported by one of three trials that recruited HIV-negative people.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.8. Opportunistic infections</HEADING>
<P>Based on data from two included trials, <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK> and <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>, it is uncertain whether corticosteroids have an effect on the risk of opportunistic infections in HIV-positive people (RR 0.95, 95% CI 0.61 to 1.48; 517 participants, 2 trials; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>). We assessed the certainty of this evidence as very low. We downgraded the evidence by two for imprecision, as the CI ranges from substantial benefits to clinically important harms. We further downgraded by one for study limitations, given that one of the two trials has a high risk of bias.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Colchicine versus placebo</HEADING>
<P>From the results of one trial among 33 HIV-positive people (<LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>), it is uncertain whether colchicine has an effect on the risk of deaths from all causes (RR 0.74, 95% CI 0.17 to 3.12; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) or constrictive pericarditis (RR 1.11, 95% CI 0.21 to 5.76; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). We assessed the certainty of the evidence for each outcome as very low. We downgraded the evidence by two for imprecision, as the CI ranges from substantial benefits to clinically important harms. We further downgraded by one for study limitations, given that the included trial has a high risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. <I>M. indicus pranii </I>versus placebo</HEADING>
<P>One trial evaluated the effects of <I>M. indicus pranii</I> immunotherapy in a two-by-two factorial design among 1250 people aged 18 years or older in Zimbabwe, South Africa, Sierra Leone, Uganda, Nigeria, Mozambique, Malawi, and Kenya (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>).</P>
<P>The trial reveals uncertainty about the effects of <I>M. indicus pranii </I>on deaths from all causes (RR 1.07, 95% CI 0.56 to 2.03; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>), deaths from pericarditis (RR 1.50, 95% CI 0.44 to 5.15; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>), constrictive pericarditis (RR 1.56, 95% CI 0.71 to 3.42; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>), repeat pericardiocenthesis (RR 1.21, 95% CI 0.96 to 1.52; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>), cancer (RR 3.03, 95% CI 0.12 to 75.37; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>), hospitalization (RR 1.22, 95% CI 0.70 to 2.13; <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>), and opportunistic infections (RR 0.67, 95% CI from 0.11 to 3.90; <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>) in HIV-negative people. The certainty of the evidence was very low for all the outcomes. We downgraded the evidence by two for imprecision, as the CIs for all outcomes range from substantial benefits to clinically important harms. We further downgraded by one for possibility of publication bias, as only one trial has so far reported data on this intervention.</P>
<P>Similar to HIV-negative people, among people living with HIV, we are also uncertain whether <I>M. indicus pranii</I> has an effect on the risk of deaths from all causes (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>), deaths from pericarditis (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>), constrictive pericarditis (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>), repeat pericardiocenthesis (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>), cancer (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>), hospitalization (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>), or opportunistic infections (<LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>) as the current evidence is of very low certainty. There were too few HIV-positive patients on antiretroviral treatment to assess the effects of <I>M. indicus pranii</I> in this group of participants. We downgraded the evidence by two for imprecision, as the CIs for all outcomes range from clinically important benefits to substantial increases in harms. We further downgraded by one for possibility of publication bias, as only one trial has so far reported data on this intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Open surgical drainage for effusion versus no drainage</HEADING>
<P>One trial, conducted in South Africa, assessed the effects of routine open surgical drainage on admission to hospital compared to no intervention among 122 participants with tuberculous pericardial effusion (<LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>). This trial started before the onset of the HIV epidemic in South Africa and, although no HIV testing was done, we have assumed the participants to be HIV-negative.</P>
<P>The results of the trial show that open surgical drainage may reduce the risk of reaccumulation of fluid requiring repeat pericardiocentesis in people without HIV infection (RR 0.23, 95% CI 0.07 to 0.76; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>). However, the intervention may make little or no difference to any other outcome measured in the study; including deaths from all causes (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>), deaths from pericarditis (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>), and pericardiectomy (<LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>). We rated the certainty of the evidence for each of these outcomes as low. We downgraded the evidence by one for imprecision, as the CIs for most outcomes range from clinically important benefits to little or no effect. We further downgraded by one for possibility of publication bias, as only one trial has so far reported data on this intervention.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-07-31 01:45:58 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2017-07-31 01:45:58 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane Review published in 2002 (<LINK REF="REF-Mayosi-2002" TYPE="REFERENCE">Mayosi 2002</LINK>). Seven randomized controlled trials (RCTs) met the inclusion criteria of this review, and all were conducted in sub-Saharan Africa. The 2002 review included four trials (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>). In addition to updated outcome data from two previously included trials (<LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>), we have included three new trials in this update (<LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>; <LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>). Four studies are at low risk of bias (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>), and three are at high risk of bias (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>). The included trials enrolled 1959 participants (54% of them HIV-positive). Six trials evaluated corticosteroids (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>), and one each evaluated colchicine (<LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>), <I>M. indicus pranii</I> immunotherapy (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>), and open surgical drainage of pericardial effusion (<LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>).</P>
<P>The key findings from these studies are as follows.</P>
<UL>
<LI>In people without HIV infection, corticosteroids probably reduce deaths from pericarditis (<I>moderate certainty evidence</I>) and may reduce deaths from all causes and the need for repeat pericardiocentesis (<I>low certainty evidence</I>). However, it is uncertain whether corticosteroids have an effect on any other outcome among HIV-negative people (<I>very low certainty evidence</I>) (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</LI>
<LI>In people living with HIV and not on antiretroviral drugs, corticosteroids may reduce constrictive pericarditis and hospitalization (<I>low certainty evidence</I>). However, corticosteroids may make little or no difference to the need for repeat pericardiocentesis (<I>low certainty evidence</I>) and it is uncertain whether the intervention has an effect on deaths or any other outcome in HIV-positive people (<I>very low certainty evidence</I>) (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</LI>
<LI>It is uncertain whether colchicine has an effect on any outcome among HIV-positive people (<I>very low certainty evidence</I>). All participants were on antiretroviral treatment.</LI>
<LI>It is uncertain whether <I>M. indicus pranii</I> has an effect on the risk of deaths or any other outcome, regardless of HIV status (<I>very low certainty evidence</I>).</LI>
<LI>In people without HIV infection, routine open surgical drainage for effusion may reduce the need for repeat pericardiocentesis, but may make little or no difference to any other outcome (<I>low certainty evidence</I>).</LI>
</UL>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-07-05 15:04:42 +0100" MODIFIED_BY="[Empty name]">
<P>We found that adjunctive corticosteroids may lead to a modest relative reduction of about 20% on the risk of all-cause mortality among HIV-negative people. Before the biggest trial on the subject was published (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>), two small trials, <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK> and <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>, had previously suggested that adjunctive corticosteroids may reduce mortality by 35% among HIV-negative patients (<LINK REF="REF-Ntsekhe-2003" TYPE="REFERENCE">Ntsekhe 2003</LINK>). Regarding people living with HIV, currently available data suggest a relative reduction of 9% in mortality, but the CI ranges very widely from a 66% relative reduction to a massive 142% relative increase in mortality. Before the publication of the big trial, <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>, data from one small trial suggested that the use of adjunctive corticosteroids among HIV-positive people with tuberculous pericarditis would result in a 50% relative reduction in mortality (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>).</P>
<P>Evidence from small early trials on health interventions is often untrustworthy (<LINK REF="REF-Wiysonge-2014" TYPE="REFERENCE">Wiysonge 2014</LINK>). An examination of more than 85,000 binary-outcome forest plots from more than 3000 Cochrane Reviews found that most large treatment effects emerged from small trials and when additional larger trials were performed, the effect sizes typically became much smaller (<LINK REF="REF-Pereira-2012" TYPE="REFERENCE">Pereira 2012</LINK>).</P>
<P>Apart from corticosteroids, we found only one trial each that assessed the effects of colchicine (<LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>), <I>M. indicus pranii </I>immunotherapy (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>), and open surgical drainage (<LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>).</P>
<P>There is unclear evidence regarding the relationship between corticosteroids, <I>M. indicus pranii</I>, and increased rates of cancer. This merits further study. One trial found an association between increased rates of cancer among people randomized to receive both<I> M. indicus pranii</I> and corticosteroids (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). However, this trial was inadequately powered to determine whether this effect was due to corticosteroids alone, <I>M. indicus pranii</I> alone, or a synergistic action between the two interventions.</P>
<P>We aimed to identify the optimal drug combination and treatment duration, but found no eligible trials. This is an important question in the light of the recent demonstration that the concentrations of rifampicin, ethambutol, and pyrazinamide in pericardial fluid based on current treatment regimens were dramatically low and below the minimum inhibitory concentrations of <I>M. tuberculosis </I>(<LINK REF="REF-Shenje-2015" TYPE="REFERENCE">Shenje 2015</LINK>). Furthermore, patients with culture-confirmed tuberculous pericarditis have a high bacillary burden, and this bacterial burden drives mortality (<LINK REF="REF-Pasipanodya-2015" TYPE="REFERENCE">Pasipanodya 2015</LINK>). Therefore the design of a highly bactericidal regimen for this condition is needed, and testing of its effectiveness in RCTs.</P>
<P>Currently there are no RCTs studying the issue of timing of pericardiectomy in people with a diagnosis of tuberculous constrictive pericarditis. The current recommendation of pericardiectomy for persistent signs of constriction after at least six weeks of antituberculous chemotherapy is based on expert opinion (<LINK REF="REF-Commerford-1991" TYPE="REFERENCE">Commerford 1991</LINK>; <LINK REF="REF-Mutyaba-2014" TYPE="REFERENCE">Mutyaba 2014</LINK>).</P>
<P>In addition, we found no eligible completed trials that assessed the effects of percutaneous drainage of the pericardium under local anaesthesia, intrapericardial fibrinolysis (<LINK REF="REF-Augustin-2011" TYPE="REFERENCE">Augustin 2011</LINK>), nor novel therapies such as cellular therapy, use of repurposed drugs, and cytokine therapy (<LINK REF="REF-Zumla-2015" TYPE="REFERENCE">Zumla 2015</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-07-06 09:57:54 +0100" MODIFIED_BY="[Empty name]">
<P>We included seven RCTs in this review. In the GRADE system, RCTs without important limitations constitute high certainty evidence. However, the system considers five factors that can lower the certainty of the evidence: study limitations, heterogeneity, indirectness, imprecision, and publication bias (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>). Four included studies were well-conducted RCTs (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>; <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>), at a low overall risk of bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Each of the remaining three trials had a high overall risk of bias (<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>; <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>; <LINK REF="STD-Liebenberg-2016" TYPE="STUDY">Liebenberg 2016</LINK>). These study limitations, as well as the imprecision of most effects, had an important impact on our rating of the certainty of the evidence (see the 'Summary of findings' tables: <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-06-25 22:56:07 +0100" MODIFIED_BY="[Empty name]">
<P>We minimized potential biases in the review process by adhering to the guidelines of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We conducted comprehensive searches of both peer-reviewed and grey literature, without limiting the searches to a specific language. Two review authors independently assessed study eligibility, extracted data, and assessed the risk of bias in each included trial. When a potentially eligible study was conducted by review co-authors, we requested independent researchers (who were not involved in the article under consideration) to assess eligibility and (if eligible for inclusion) extract data (<LINK REF="REF-Kliner-2014" TYPE="REFERENCE">Kliner 2014</LINK>).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-07-31 01:14:43 +0100" MODIFIED_BY="[Empty name]">
<P>The previously published version of this Cochrane Review, <LINK REF="REF-Mayosi-2002" TYPE="REFERENCE">Mayosi 2002</LINK>, found that corticosteroids could have important clinical benefits in both HIV-negative and HIV-positive people. However, the three included trials were too small to demonstrate a significant effect (<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>; <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>; <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>). The review authors also included one trial that examined open surgical drainage compared with conservative management, and showed that surgery relieved cardiac tamponade (<LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>). A year later, Ntsekhe and colleagues published a systematic review of the effectiveness of adjunctive corticosteroids in tuberculous pericarditis, in which they concluded that corticosteroids could have large beneficial effects on mortality and morbidity in tuberculous pericarditis but published trials were too small to be conclusive (<LINK REF="REF-Ntsekhe-2003" TYPE="REFERENCE">Ntsekhe 2003</LINK>). No other systematic review of treatments for tuberculous pericarditis has been published since then.</P>
<P>
<LINK REF="REF-Imazio-2015" TYPE="REFERENCE">Imazio 2015</LINK> published a systematic review on the causes, diagnosis, therapy, prevention, and prognosis of pericarditis. However, the authors focused the treatment component of the review on interventions for idiopathic and viral pericarditis in North America and Europe.</P>
<P>This Cochrane Review is therefore the most comprehensive review to date on interventions for treating tuberculous pericarditis.The review's findings are slightly different to the largest trial ever completed, authored by some of the authors of this review, which showed no significant difference for corticosteroids on a composite outcome reflecting benefit, and a slight increase in HIV-associated cancer . The finessing of the results and the interpretation is probably due to multiple factors, including combining with other studies; and re-analysing the the original trial data stratified by HIV status.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-07-31 01:15:00 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2017-07-31 01:15:00 +0100" MODIFIED_BY="[Empty name]">
<P>Our review shows that corticosteroids and open surgical drainage have evidence of benefit in people with tuberculous pericarditis.</P>
<P>In HIV-negative people, corticosteroids probably reduce deaths from pericarditis (<I>moderate certainty evidence</I>) and may reduce deaths from all causes (<I>low certainty evidence</I>) and the need for repeat pericardiocentesis (<I>low certainty evidence</I>); while open surgical drainage may reduce the subsequent need for pericardiocentesis (<I>low certainty evidence</I>).</P>
<P>In the treatment of people living with HIV not on antiretroviral drugs, corticosteroids may reduce constrictive pericarditis (<I>low certainty evidence</I>) and hospitalizations (<I>low certainty evidence</I>); with little or no effect on deaths (<I>low certainty evidence</I>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-06-25 23:49:59 +0100" MODIFIED_BY="[Empty name]">
<P>The relationship between corticosteroids, immunomodulators, and increased rates of cancer needs to be investigated further. In addition, high-quality randomized trials are needed on percutaneous drainage of the pericardium under local anaesthesia, the timing of pericardiectomy in tuberculous constrictive pericarditis, new antibiotic regimens, cellular therapy, use of repurposed drugs, and cytokine therapy.</P>
<P>We will update this Cochrane Review when the ongoing trial of intrapericardial fibrinolysis is published (<LINK REF="STD-NCT02673879" TYPE="STUDY">NCT02673879</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-07-31 01:45:58 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Paul Garner and David Sinclair for guidance in the preparation of this Cochrane Review. </P>
<P>We are also grateful to Patrick Commerford, for contributing to earlier versions of this review.</P>
<P>Charles S Wiysonge's work is supported by the South African Medical Research Council, the National Research Foundation of South Africa (Grant Numbers: 106035 and 108571), and by the Effective Health Care Research Consortium. This Consortium and the CIDG editorial base are funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this publication do not necessarily reflect UK government policy.</P>
<P>The work of BM Mayosi is funded by the South African Medical Research Council, the National Research Foundation of South Africa, the Wellcome Trust, and the Lily and Ernst Hausmann Research Trust.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-07-31 12:24:45 +0100" MODIFIED_BY="[Empty name]">
<P>Mpiko Ntsekhe, Lehana Thabane, Freedom Gumedze, Shaheen Pandie, and Bongani M Mayosi were investigators in an included study (<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>). Jimmy Volmink was a member of the Data Safety and Monitoring Committee for the same study. However, two review authors (CSW and DM) who were not involved in this trial independently extracted the data for this study, which were verified by Paul Garner, David Sinclair, Hannah Ryan, and Maya Tickell-Painter.</P>
<P>Charles S Wiysonge, Mpiko Ntsekhe, Jimmy Volmink, and Bongani M Mayosi were co-authors of a study assessed and excluded from the review (<LINK REF="STD-Wiysonge-2008" TYPE="STUDY">Wiysonge 2008</LINK>). A review author (DM) who was not involved in this study initially assessed the eligibility of this study.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-07-31 12:24:08 +0100" MODIFIED_BY="[Empty name]">
<P>Charles S Wiysonge and Bongani M Mayosi led the preparation of the current version of the review, with important intellectual inputs from all co-authors.<BR/>Charles S Wiysonge and Bongani M Mayosi were involved in all stages of the review.<BR/>Dumisani Majombozi was involved in screening of searches, study selection, data extraction, and verification of data analysis.<BR/>Freedom Gumedze provided the data on the <LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK> trial and verified the data analysis.<BR/>Mpiko Ntsekhe, Lehana Thabane, Jimmy Volmink, and Shaheen Pandie read and provided important input into successive drafts of the review.<BR/>All review authors read and approved the final version of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-07-31 12:22:52 +0100" MODIFIED_BY="[Empty name]">
<P>There are differences between the authors of the protocol and the current version of the review. The protocol had three authors (Bongani Mayosi, Jimmy Volmink, and Patrick Commerford), while this review update has eight review authors.</P>
<P>The protocol set out to assess the effects of only four interventions (six-month antituberculous drug regimens compared with regimens of nine months or more, corticosteroids, pericardial drainage, and pericardiectomy). However, in this review we have assessed the effects of any intervention used to treat tuberculous pericarditis.</P>
<P>The protocol did not report cancer as a potential outcome, but we have reported outcome data on cancer in this version of the review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-11-10 16:52:14 +0000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-09-10 11:09:06 +0100" MODIFIED_BY="Deirdre Walshe">
<STUDIES MODIFIED="2017-06-27 20:47:30 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2017-06-27 20:46:55 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Hakim-2000" MODIFIED="2017-06-27 20:45:54 +0100" MODIFIED_BY="[Empty name]" NAME="Hakim 2000" YEAR="2000">
<REFERENCE MODIFIED="2017-06-27 20:45:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hakim J, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A</AU>
<TI>Double blind randomised placebo controlled trial of adjuvant prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients</TI>
<SO>Heart</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>2</NO>
<PG>183-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3382849"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-27 20:45:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hakim JG, Ternouth I, Mushangi E</AU>
<TI>Mortality in patients with HIV-related tuberculous pericarditis (TBP) treated with adjunctive prednisolone [abstract]. International Clinical Epidemiology Network. Abstracts of the INCLEN XV Global Meeting, 1998, Queretaro, Mexico</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>Suppl 1</NO>
<PG>5S</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3382850"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3382848"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liebenberg-2016" MODIFIED="2017-06-27 20:44:53 +0100" MODIFIED_BY="[Empty name]" NAME="Liebenberg 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-06-27 20:44:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liebenberg JJ, Dold CJ, Olivier LR</AU>
<TI>A prospective investigation into the effect of colchicine on tuberculous pericarditis</TI>
<SO>Cardiovascular Journal of Africa</SO>
<YR>2016</YR>
<VL>27</VL>
<NO>6</NO>
<PG>350-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6678223"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6678222"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mayosi-2014" MODIFIED="2017-06-27 20:45:12 +0100" MODIFIED_BY="[Empty name]" NAME="Mayosi 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-06-27 20:45:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F, et al</AU>
<TI>Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2014</YR>
<VL>371</VL>
<NO>12</NO>
<PG>1121-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3382852"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-27 20:45:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mayosi BM, Ntsekhe M, Bosch J, Pogue J, Gumedze F, Badri M, et al</AU>
<TI>Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: a 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis</TI>
<SO>American Heart Journal</SO>
<YR>2013</YR>
<VL>165</VL>
<NO>2</NO>
<PG>109-15.e3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3382853"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3382851"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reuter-2006" MODIFIED="2017-06-27 20:46:05 +0100" MODIFIED_BY="[Empty name]" NAME="Reuter 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-06-27 20:46:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reuter H, Burgess LJ, Louw VJ, Doubell AF</AU>
<TI>Experience with adjunctive corticosteroids in managing tuberculous pericarditis</TI>
<SO>Cardiovascular Journal of South Africa</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>5</NO>
<PG>233-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3382855"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3382854"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schrire-1959" MODIFIED="2017-06-27 20:46:20 +0100" MODIFIED_BY="[Empty name]" NAME="Schrire 1959" YEAR="1959">
<REFERENCE MODIFIED="2017-06-27 20:46:20 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Schrire V. Experience with pericarditis at Groote Schuur Hospital, Cape Town: An analysis of one hundred and sixty cases over a six-year period. S Afr Med J 1959;33:810-17.&lt;/p&gt;" NOTES_MODIFIED="2017-06-27 20:46:20 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schrire V</AU>
<TI>Experience with pericarditis at Groote Schuur Hospital, Cape Town: an analysis of one hundred and sixty cases over a six-year period</TI>
<SO>South African Medical Journal</SO>
<YR>1959</YR>
<VL>33</VL>
<PG>810-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3382857"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3382856"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Strang-2004a" MODIFIED="2017-06-27 20:46:36 +0100" MODIFIED_BY="[Empty name]" NAME="Strang 2004a" YEAR="1987">
<REFERENCE MODIFIED="2017-06-27 20:46:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Strang JI, Nunn AJ, Johnson DA, Casbard A, Gibson DG, Girling DJ</AU>
<TI>Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up</TI>
<SO>QJM</SO>
<YR>2004</YR>
<VL>97</VL>
<NO>8</NO>
<PG>525-35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3382859"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-27 20:46:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strang JIG, Kakaza HHS, Gibson DG, Girling DJ, Nunn AJ, Fox W</AU>
<TI>Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis</TI>
<SO>Lancet</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>8573</NO>
<PG>1418-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3382860"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3382858"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Strang-2004b" MODIFIED="2017-06-27 20:46:55 +0100" MODIFIED_BY="[Empty name]" NAME="Strang 2004b" YEAR="1988">
<REFERENCE MODIFIED="2017-06-27 20:46:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Strang JI, Nunn AJ, Johnson DA, Casbard A, Gibson DG, Girling DJ</AU>
<TI>Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up</TI>
<SO>QJM</SO>
<YR>2004</YR>
<VL>97</VL>
<NO>8</NO>
<PG>525-35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3382862"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-06-27 20:46:45 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Strang JIG, Kakaza HHS, Gibson DG, Allen BW, Mitchison DA, et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet 1988;ii:759-764.&lt;/p&gt;" NOTES_MODIFIED="2017-06-27 20:46:45 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strang JIG, Kakaza HHS, Gibson DG, Allen BW, Mitchison DA, Evans DJ, et al</AU>
<TI>Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei</TI>
<SO>Lancet</SO>
<YR>1988</YR>
<VL>2</VL>
<NO>8614</NO>
<PG>759-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3382863"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3382861"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-06-27 20:47:07 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Wiysonge-2008" MODIFIED="2017-06-27 20:47:07 +0100" MODIFIED_BY="[Empty name]" NAME="Wiysonge 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-06-27 20:47:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiysonge CS, Ntsekhe M, Gumedze F, Sliwa K, Blackett KN, Commerford PJ, et al</AU>
<TI>Contemporary use of adjunctive corticosteroids in tuberculous pericarditis</TI>
<SO>International Journal of Cardiology</SO>
<YR>2008</YR>
<VL>124</VL>
<NO>3</NO>
<PG>388-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3382865"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3382864"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-06-27 20:47:18 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Cui-2005" MODIFIED="2017-06-27 20:47:18 +0100" MODIFIED_BY="[Empty name]" NAME="Cui 2005" YEAR="2005">
<REFERENCE MODIFIED="2017-06-27 20:47:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cui HB, Chen XY, Cui CC, Shou XL, Liu XH, Yao XW, et al</AU>
<TI>Prevention of pericardial constriction by transcatheter intrapericardial fibrinolysis with urokinase</TI>
<SO>Chinese Medical Sciences Journal</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>1</NO>
<PG>5-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3382867"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3382866"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2017-06-27 20:47:30 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02673879" MODIFIED="2017-06-27 20:47:30 +0100" MODIFIED_BY="[Empty name]" NAME="NCT02673879" YEAR="2016">
<REFERENCE MODIFIED="2017-06-27 20:47:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02673879</AU>
<TI>IMPI 2 - A Trial of Intrapericardial Alteplase in Large Pericardial Effusion (IMPI-2)</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT02673879</SO>
<YR>(first received 1 February 2016)</YR>
<IDENTIFIERS MODIFIED="2017-05-10 16:30:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="6678225"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-03-28 13:51:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="6678224"/><IDENTIFIER MODIFIED="2017-03-28 13:51:48 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT02673879"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-06-30 10:34:47 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2017-06-30 10:34:47 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alzeer-1993" MODIFIED="2017-06-30 10:33:55 +0100" MODIFIED_BY="[Empty name]" NAME="Alzeer 1993" TYPE="JOURNAL_ARTICLE">
<AU>Alzeer AH, FitzGerald JM</AU>
<TI>Corticosteroids and tuberculosis: risks and use as adjunct therapy</TI>
<SO>Tubercle and Lung Disease</SO>
<YR>1993</YR>
<VL>74</VL>
<NO>1</NO>
<PG>6-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Augustin-2011" MODIFIED="2017-06-27 20:47:40 +0100" MODIFIED_BY="[Empty name]" NAME="Augustin 2011" TYPE="JOURNAL_ARTICLE">
<AU>Augustin P, Desmard M, Mordant P, Lasocki S, Maury JM, Heming N, et al</AU>
<TI>Clinical review: intrapericardial fibrinolysis in management of purulent pericarditis</TI>
<SO>Critical Care</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>2</NO>
<PG>220</PG>
<IDENTIFIERS MODIFIED="2015-05-02 07:06:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-05-02 07:06:36 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1186/cc10022"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2017-06-27 20:47:49 +0100" MODIFIED_BY="[Empty name]" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem B, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhan-1980" MODIFIED="2017-06-27 20:47:56 +0100" MODIFIED_BY="[Empty name]" NAME="Bhan 1980" TYPE="JOURNAL_ARTICLE">
<AU>Bhan GL</AU>
<TI>Tuberculous pericarditis</TI>
<SO>Journal of Infection</SO>
<YR>1980</YR>
<VL>2</VL>
<NO>4</NO>
<PG>360-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cegielski-1990" MODIFIED="2017-06-27 20:48:07 +0100" MODIFIED_BY="[Empty name]" NAME="Cegielski 1990" TYPE="JOURNAL_ARTICLE">
<AU>Cegielski JP, Ramaiya K, Lallinger GJ, Mtulia IA, Mbaga IM</AU>
<TI>Pericardial disease and human immunodeficiency virus in Dar es Salaam, Tanzania</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<NO>8683</NO>
<PG>209-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cisneros-1996" MODIFIED="2017-06-30 10:34:06 +0100" MODIFIED_BY="[Empty name]" NAME="Cisneros 1996" TYPE="JOURNAL_ARTICLE">
<AU>Cisneros JR, Murray KM</AU>
<TI>Corticosteroids in tuberculosis</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1996</YR>
<VL>30</VL>
<NO>11</NO>
<PG>1298-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Commerford-1991" MODIFIED="2017-06-27 20:48:14 +0100" MODIFIED_BY="[Empty name]" NAME="Commerford 1991" TYPE="BOOK_SECTION">
<AU>Commerford PJ, Strang JIG</AU>
<TI>Tuberculous pericarditis</TI>
<SO>A Century of Tuberculosis: South African Perspectives</SO>
<YR>1991</YR>
<ED>Coovadia HM, Benatar SR</ED>
<PB>Oxford University Press</PB>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Desai-1979" MODIFIED="2017-06-27 20:48:22 +0100" MODIFIED_BY="[Empty name]" NAME="Desai 1979" TYPE="JOURNAL_ARTICLE">
<AU>Desai HN</AU>
<TI>Tuberculous pericarditis: a review of 100 cases</TI>
<SO>South African Medical Journal</SO>
<YR>1979</YR>
<VL>55</VL>
<NO>22</NO>
<PG>877-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dooley-1997" MODIFIED="2017-06-30 10:34:14 +0100" MODIFIED_BY="[Empty name]" NAME="Dooley 1997" TYPE="JOURNAL_ARTICLE">
<AU>Dooley DP, Carpenter JL, Rademacher S</AU>
<TI>Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>4</NO>
<PG>872-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fowler-1991" MODIFIED="2017-06-27 20:48:55 +0100" MODIFIED_BY="[Empty name]" NAME="Fowler 1991" TYPE="JOURNAL_ARTICLE">
<AU>Fowler NO</AU>
<TI>Tuberculous pericarditis</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>266</VL>
<NO>1</NO>
<PG>99-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fowler-1992" MODIFIED="2017-06-30 10:34:21 +0100" MODIFIED_BY="[Empty name]" NAME="Fowler 1992" TYPE="JOURNAL_ARTICLE">
<AU>Fowler NO</AU>
<TI>Pericardial disease</TI>
<SO>Heart Disease &amp; Stroke</SO>
<YR>1992</YR>
<VL>1</VL>
<NO>2</NO>
<PG>85-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fowler-1995" MODIFIED="2017-06-30 10:34:26 +0100" MODIFIED_BY="[Empty name]" NAME="Fowler 1995" TYPE="JOURNAL_ARTICLE">
<AU>Fowler NO</AU>
<TI>Constrictive pericarditis: its history and current status</TI>
<SO>Clinical Cardiology</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>6</NO>
<PG>341-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ganju-1990" MODIFIED="2017-06-27 20:49:45 +0100" MODIFIED_BY="[Empty name]" NAME="Ganju 1990" TYPE="JOURNAL_ARTICLE">
<AU>Ganju L, Mukherjee R, Batra HV, Talwar GP</AU>
<TI>Immuno-blot analysis of antigens of Mycobacterium w: a candidate anti-leprosy vaccine using monoclonal antibodies and patient sera</TI>
<SO>Zentralblatt für Bakteriologie</SO>
<YR>1990</YR>
<VL>273</VL>
<NO>3</NO>
<PG>378&#8211;85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gelfand-1957" MODIFIED="2008-11-10 16:15:24 +0000" MODIFIED_BY="[Empty name]" NAME="Gelfand 1957" TYPE="BOOK_SECTION">
<AU>Gelfand M</AU>
<TI>The Sick African</TI>
<SO>The Sick African</SO>
<YR>1957</YR>
<PG>447</PG>
<EN>3rd</EN>
<PB>Juta</PB>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-GDT-2014" MODIFIED="2017-06-27 21:26:31 +0100" MODIFIED_BY="[Empty name]" NAME="GRADEpro GDT 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro GDT</TI>
<YR>2014</YR>
<EN>accessed 15 September 2014</EN>
<PB>GRADE Working Group, McMaster University</PB>
<CY>Hamilton (ON)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2017-06-27 20:49:54 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harvey-1937" NAME="Harvey 1937" TYPE="JOURNAL_ARTICLE">
<AU>Harvey AM, Whitehill MR</AU>
<TI>Tuberculous pericarditis</TI>
<SO>Medicine</SO>
<YR>1937</YR>
<VL>16</VL>
<PG>45-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-06-27 20:50:27 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S, editor(s)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imazio-2015" MODIFIED="2017-06-27 20:50:18 +0100" MODIFIED_BY="[Empty name]" NAME="Imazio 2015" TYPE="JOURNAL_ARTICLE">
<AU>Imazio M, Gaita F, LeWinter M</AU>
<TI>Evaluation and treatment of pericarditis: a systematic review</TI>
<SO>JAMA</SO>
<YR>2015</YR>
<VL>314</VL>
<NO>14</NO>
<PG>1498-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kliner-2014" MODIFIED="2017-06-01 16:38:07 +0100" MODIFIED_BY="[Empty name]" NAME="Kliner 2014" TYPE="OTHER">
<AU>Kliner M, Garner P</AU>
<TI>When trial authors write Cochrane Reviews: competing interests need to be better managed [editorial]</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<VL>9</VL>
<PG>10.1002/14651858.ED000089</PG>
<IDENTIFIERS MODIFIED="2017-06-01 16:38:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Koh-1994" MODIFIED="2017-06-27 20:50:37 +0100" MODIFIED_BY="[Empty name]" NAME="Koh 1994" TYPE="JOURNAL_ARTICLE">
<AU>Koh KK, Kim EJ, Cho CH, Choi MJ, Cho SK, Kim SS, et al</AU>
<TI>Adenosine deaminase and carcinoembryonic antigen in pericardial effusion diagnosis, especially in suspected tuberculous pericarditis</TI>
<SO>Circulation</SO>
<YR>1994</YR>
<VL>89</VL>
<NO>6</NO>
<PG>2728-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawn-2011" MODIFIED="2017-06-27 20:50:44 +0100" MODIFIED_BY="[Empty name]" NAME="Lawn 2011" TYPE="JOURNAL_ARTICLE">
<AU>Lawn SD, Zumla AI</AU>
<TI>Tuberculosis</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>378</VL>
<NO>9785</NO>
<PG>57&#8211;72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2017-06-27 20:50:51 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lorell-1997" MODIFIED="2017-06-27 20:51:18 +0100" MODIFIED_BY="[Empty name]" NAME="Lorell 1997" TYPE="BOOK_SECTION">
<AU>Lorell BH</AU>
<TI>Pericardial diseases</TI>
<SO>Heart disease: a Textbook of Cardiovascular Medicine</SO>
<YR>1997</YR>
<ED>Braunwald E</ED>
<PB>W.B. Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lucas-1993" MODIFIED="2017-06-27 20:57:37 +0100" MODIFIED_BY="[Empty name]" NAME="Lucas 1993" TYPE="JOURNAL_ARTICLE">
<AU>Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N&#8217;Gbichi JM, et al</AU>
<TI>The mortality and pathology of HIV infection in a West African city</TI>
<SO>AIDS</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>12</NO>
<PG>1569-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maartens-2007" MODIFIED="2017-06-27 20:51:25 +0100" MODIFIED_BY="[Empty name]" NAME="Maartens 2007" TYPE="JOURNAL_ARTICLE">
<AU>Maartens G, Wilkinson RJ</AU>
<TI>Tuberculosis</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<NO>9604</NO>
<PG>2030&#8211;43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayosi-2005" MODIFIED="2017-06-27 20:51:34 +0100" MODIFIED_BY="[Empty name]" NAME="Mayosi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mayosi BM, Burgess LJ, Doubell AF</AU>
<TI>Tuberculous pericarditis</TI>
<SO>Circulation</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>23</NO>
<PG>3608-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayosi-2006" MODIFIED="2017-06-27 20:51:46 +0100" MODIFIED_BY="[Empty name]" NAME="Mayosi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mayosi BM, Wiysonge CS, Ntsekhe M, Volmink JA, Gumedze F, Maartens G, et al</AU>
<TI>Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mayosi-2008" MODIFIED="2017-06-27 20:51:54 +0100" MODIFIED_BY="[Empty name]" NAME="Mayosi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Mayosi BM, Wiysonge CS, Ntsekhe M, Gumedze F, Volmink JA, Maartens G, et al</AU>
<TI>Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa</TI>
<SO>South African Medical Journal</SO>
<YR>2008</YR>
<VL>98</VL>
<NO>1</NO>
<PG>36-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mutyaba-2014" MODIFIED="2017-06-27 20:52:03 +0100" MODIFIED_BY="[Empty name]" NAME="Mutyaba 2014" TYPE="JOURNAL_ARTICLE">
<AU>Mutyaba AK, Balkaran S, Cloete R, du Plessis N, Badri M, Brink J, et al</AU>
<TI>Constrictive pericarditis requiring pericardiectomy at Groote Schuur Hospital, Cape Town, South Africa: causes and perioperative outcomes in the HIV era (1990-2012)</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2014</YR>
<VL>148</VL>
<NO>6</NO>
<PG>3058-65.e1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ntsekhe-2003" MODIFIED="2017-06-27 20:52:15 +0100" MODIFIED_BY="[Empty name]" NAME="Ntsekhe 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ntsekhe M, Wiysonge C, Volmink JA, Commerford PJ, Mayosi BM</AU>
<TI>Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven</TI>
<SO>QJM</SO>
<YR>2003</YR>
<VL>96</VL>
<NO>8</NO>
<PG>593-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ntsekhe-2005" MODIFIED="2017-06-27 20:52:23 +0100" MODIFIED_BY="[Empty name]" NAME="Ntsekhe 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ntsekhe M, Hakim J</AU>
<TI>Impact of human immunodeficiency virus infection on cardiovascular disease in Africa</TI>
<SO>Circulation</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>23</NO>
<PG>3602-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ntsekhe-2008" MODIFIED="2017-06-27 20:52:32 +0100" MODIFIED_BY="[Empty name]" NAME="Ntsekhe 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ntsekhe M, Wiysonge CS, Gumedze F, Maartens G, Commerford PJ, Volmink JA, et al</AU>
<TI>HIV infection is associated with a lower incidence of constriction in presumed tuberculous pericarditis: a prospective observational study</TI>
<SO>PLoS ONE</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>6</NO>
<PG>e2253</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ntsekhe-2012" MODIFIED="2017-06-27 20:52:46 +0100" MODIFIED_BY="[Empty name]" NAME="Ntsekhe 2012" TYPE="JOURNAL_ARTICLE">
<AU>Ntsekhe M, Shey Wiysonge C, Commerford PJ, Mayosi BM</AU>
<TI>The prevalence and outcome of effusive constrictive pericarditis: a systematic review of the literature</TI>
<SO>Cardiovascular Journal of Africa</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>5</NO>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ntsekhe-2013" MODIFIED="2017-06-27 20:52:54 +0100" MODIFIED_BY="[Empty name]" NAME="Ntsekhe 2013" TYPE="JOURNAL_ARTICLE">
<AU>Ntsekhe M, Mayosi BM</AU>
<TI>Tuberculous pericarditis with and without HIV</TI>
<SO>Heart Failure Reviews</SO>
<YR>2013</YR>
<VL>18</VL>
<NO>3</NO>
<PG>367-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pandie-2014" MODIFIED="2017-06-27 20:53:02 +0100" MODIFIED_BY="[Empty name]" NAME="Pandie 2014" TYPE="JOURNAL_ARTICLE">
<AU>Pandie S, Engel ME, Kerbelker ZS, Mayosi BM</AU>
<TI>Mycobacterium w immunotherapy for treating pulmonary tuberculosis - a systematic review</TI>
<SO>Current Pharmaceutical Design</SO>
<YR>2014</YR>
<VL>20</VL>
<NO>39</NO>
<PG>6207-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pasipanodya-2015" MODIFIED="2017-06-27 20:53:10 +0100" MODIFIED_BY="[Empty name]" NAME="Pasipanodya 2015" TYPE="JOURNAL_ARTICLE">
<AU>Pasipanodya JG, Mubanga M, Ntsekhe M, Pandie S, Magazi BT, Gumedze F, et al</AU>
<TI>Tuberculous pericarditis is multibacillary and bacterial burden drives high mortality</TI>
<SO>EBioMedicine</SO>
<YR>2015</YR>
<VL>2</VL>
<NO>11</NO>
<PG>1634-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pereira-2012" MODIFIED="2017-06-27 20:53:22 +0100" MODIFIED_BY="[Empty name]" NAME="Pereira 2012" TYPE="JOURNAL_ARTICLE">
<AU>Pereira TV, Horwitz RI, Ioannidis JP</AU>
<TI>Empirical evaluation of very large treatment effects of medical interventions</TI>
<SO>JAMA</SO>
<YR>2012</YR>
<VL>308</VL>
<NO>16</NO>
<PG>1676-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quayle-1987" MODIFIED="2017-06-27 20:57:51 +0100" MODIFIED_BY="[Empty name]" NAME="Quayle 1987" TYPE="JOURNAL_ARTICLE">
<AU>Quayle JM, Lipschik GY, Heurich AE</AU>
<TI>Management of tuberculous pericarditis</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1987</YR>
<VL>43</VL>
<NO>6</NO>
<PG>653-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rana-1997" MODIFIED="2017-06-27 20:53:38 +0100" MODIFIED_BY="[Empty name]" NAME="Rana 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rana F, Hawken MP, Meme HK, Chakaya JM, Githui WA, Odhiambo JA, et al</AU>
<TI>Autopsy findings in HIV-1-infected adults in Kenya</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology</SO>
<YR>1997</YR>
<VL>14</VL>
<NO>1</NO>
<PG>83&#8211;5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2017-06-27 20:53:46 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager 5 (RevMan 5)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rooney-1970" MODIFIED="2017-06-30 10:34:33 +0100" MODIFIED_BY="[Empty name]" NAME="Rooney 1970" TYPE="JOURNAL_ARTICLE">
<AU>Rooney JJ, Crocco JA, Lyons HA</AU>
<TI>Tuberculous pericarditis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1970</YR>
<VL>72</VL>
<NO>1</NO>
<PG>73-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sagrist_x00e0__x002d_Sauleda-1988" MODIFIED="2017-06-27 20:53:54 +0100" MODIFIED_BY="[Empty name]" NAME="Sagristà-Sauleda 1988" TYPE="JOURNAL_ARTICLE">
<AU>Sagristà-Sauleda J, Permanya-Miralda G, Soler-Soler J</AU>
<TI>Tuberculous pericarditis: ten year experience with a prospective protocol for diagnosis and treatment</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1988</YR>
<VL>11</VL>
<NO>4</NO>
<PG>724-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saini-2009" MODIFIED="2017-06-27 20:54:01 +0100" MODIFIED_BY="[Empty name]" NAME="Saini 2009" TYPE="JOURNAL_ARTICLE">
<AU>Saini V, Raghuvanshi S, Talwar GP, Ahmed N, Khurana JP, Hasnain SE, et al</AU>
<TI>Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species</TI>
<SO>PLoS ONE</SO>
<YR>2009</YR>
<VL>4</VL>
<NO>7</NO>
<PG>e6263</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schrire-1967" MODIFIED="2017-06-30 10:34:40 +0100" MODIFIED_BY="[Empty name]" NAME="Schrire 1967" TYPE="JOURNAL_ARTICLE">
<AU>Schrire V</AU>
<TI>Pericarditis (with particular reference to tuberculous pericarditis)</TI>
<SO>Australian Annals of Medicine</SO>
<YR>1967</YR>
<VL>16</VL>
<NO>1</NO>
<PG>41-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Senderovitz-1994" MODIFIED="2017-06-30 10:34:47 +0100" MODIFIED_BY="[Empty name]" NAME="Senderovitz 1994" TYPE="JOURNAL_ARTICLE">
<AU>Senderovitz T, Viskum K</AU>
<TI>Corticosteroids and tuberculosis</TI>
<SO>Respiratory Medicine</SO>
<YR>1994</YR>
<VL>88</VL>
<NO>8</NO>
<PG>561-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shenje-2015" MODIFIED="2017-06-27 20:54:19 +0100" MODIFIED_BY="[Empty name]" NAME="Shenje 2015" TYPE="JOURNAL_ARTICLE">
<AU>Shenje J, Ifeoma Adimora-Nweke F, Ross IL, Ntsekhe M, Wiesner L, Deffur A, et al</AU>
<TI>Poor penetration of antibiotics into pericardium in pericardial tuberculosis</TI>
<SO>EBioMedicine</SO>
<YR>2015</YR>
<VL>2</VL>
<NO>11</NO>
<PG>1640-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singh-1992" MODIFIED="2017-06-27 20:54:27 +0100" MODIFIED_BY="[Empty name]" NAME="Singh 1992" TYPE="JOURNAL_ARTICLE">
<AU>Singh IG, Mukherjee R, Talwar GP, Kaufmann SH</AU>
<TI>In vitro characterization of T cells from Mycobacterium w-vaccinated mice</TI>
<SO>Infection and Immunity</SO>
<YR>1992</YR>
<VL>60</VL>
<NO>1</NO>
<PG>257-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strang-1984" MODIFIED="2017-06-27 20:54:35 +0100" MODIFIED_BY="[Empty name]" NAME="Strang 1984" TYPE="JOURNAL_ARTICLE">
<AU>Strang JIG</AU>
<TI>Tuberculous pericarditis in Transkei</TI>
<SO>Clinical Cardiology</SO>
<YR>1984</YR>
<VL>7</VL>
<NO>12</NO>
<PG>667-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strang-1997" MODIFIED="2017-06-27 20:54:44 +0100" MODIFIED_BY="[Empty name]" NAME="Strang 1997" TYPE="JOURNAL_ARTICLE">
<AU>Strang JIG</AU>
<TI>Tuberculous pericarditis</TI>
<SO>Journal of Infection</SO>
<YR>1997</YR>
<VL>35</VL>
<NO>3</NO>
<PG>215-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Syed-2007" MODIFIED="2017-06-27 20:54:51 +0100" MODIFIED_BY="[Empty name]" NAME="Syed 2007" TYPE="JOURNAL_ARTICLE">
<AU>Syed FF, Mayosi BM</AU>
<TI>A modern approach to tuberculous pericarditis</TI>
<SO>Progress in Cardiovascular Diseases</SO>
<YR>2007</YR>
<VL>50</VL>
<NO>3</NO>
<PG>218-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiysonge-2014" MODIFIED="2017-06-27 20:55:00 +0100" MODIFIED_BY="[Empty name]" NAME="Wiysonge 2014" TYPE="JOURNAL_ARTICLE">
<AU>Wiysonge CS</AU>
<TI>Immunotherapy for tuberculous pericarditis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2014</YR>
<VL>371</VL>
<NO>26</NO>
<PG>2533</PG>
<IDENTIFIERS MODIFIED="2015-04-30 01:46:39 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-04-30 01:46:35 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1056/NEJMc1413185#SA4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zumla-2015" MODIFIED="2017-06-27 20:55:11 +0100" MODIFIED_BY="[Empty name]" NAME="Zumla 2015" TYPE="JOURNAL_ARTICLE">
<AU>Zumla A, Maeurer M, Moll G, Mayosi BM</AU>
<TI>Host-directed therapies for tuberculous pericarditis</TI>
<SO>International Journal of Infectious Diseases</SO>
<YR>2015</YR>
<VL>32</VL>
<PG>30-1</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-06-25 19:48:08 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Mayosi-2000" MODIFIED="2017-06-25 19:48:08 +0100" MODIFIED_BY="[Empty name]" NAME="Mayosi 2000" TYPE="COCHRANE_REVIEW">
<AU>Mayosi BM, Volmink JA, Commerford PJ</AU>
<TI>Interventions for treating tuberculous pericarditis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<PG>CD000526</PG>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000526"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mayosi-2002" MODIFIED="2017-05-10 16:30:53 +0100" MODIFIED_BY="[Empty name]" NAME="Mayosi 2002" TYPE="COCHRANE_REVIEW">
<AU>Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ</AU>
<TI>Interventions for treating tuberculous pericarditis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<PG>CD000526</PG>
<IDENTIFIERS MODIFIED="2015-04-05 13:48:18 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-04-05 13:48:18 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000526"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-07-05 15:24:42 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-07-05 15:24:42 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-06-25 23:19:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hakim-2000">
<CHAR_METHODS MODIFIED="2017-06-25 23:19:10 +0100" MODIFIED_BY="[Empty name]">
<P>Computer-generated randomization list</P>
<P>Double blind placebo controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-25 23:19:10 +0100" MODIFIED_BY="[Empty name]">
<P>58 HIV-positive participants who were on antituberculous chemotherapy for suspected tuberculous pericarditis.</P>
<P>Inclusion criteria: (a) age 18 to 55 years; (b) residence in Harare city to ensure good follow up; (c) HIV seropositive; (d) no diagnosis of tuberculosis within the past two years; (e) large pericardial effusion on echocardiography (&gt; 1 cm anteriorly and &gt; 1 cm posteriorly; and (f) pericardial aspirate with &gt; 50% lymphocytes and protein content &gt; 30 g/L.</P>
<P>Exclusion criteria: (a) antituberculous treatment started more than 48 hours before recruitment; (b) corticosteroid treatment within previous one month; (c) presence of Kaposi&#8217;s sarcoma or any other malignancy; (d) coexisting life threatening disease; (e) bacterial pneumonia; (f) pregnancy; (g) cavitating pulmonary tuberculosis; and (h) other causes of pericardial effusion.</P>
<P>"All patients received a standard short course anti tuberculous regimen in accordance with national guidelines. This included rifampicin, isoniazid, pyrazinamide, and ethambutol for two months, followed by rifampicin and isoniazid for a further four months in standard doses."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-25 23:19:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention</B>
</P>
<UL>
<LI>Prednisolone for the first 6 weeks of antituberculous chemotherapy.</LI>
<LI>Dose for adults: 60 mg for the first week, and tapering by 10 mg every week.</LI>
</UL>
<P>
<B>Control</B>
</P>
<UL>
<LI>Placebo.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-25 23:19:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes</B>
</P>
<UL>
<LI>Death.</LI>
<LI>Resolution of pericardial effusion.</LI>
</UL>
<P>
<B>Secondary outcomes</B>
</P>
<UL>
<LI>Resolution of pretreatment symptoms and signs, and ECG changes.</LI>
<LI>Corticosteroid-related adverse effects.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-10 15:50:59 +0000" MODIFIED_BY="[Empty name]">
<P>Study location: Harare, Zimbabwe</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-25 23:24:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liebenberg-2016">
<CHAR_METHODS MODIFIED="2017-06-25 23:24:27 +0100" MODIFIED_BY="[Empty name]">
<P>Participants "were randomised to an intervention and control group using a web-based computer system that ensured assignment concealment".</P>
<P>"Upon completion of the research period, the blinding was unveiled and data were presented for statistical analysis".</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-25 23:24:27 +0100" MODIFIED_BY="[Empty name]">
<P>33 HIV-positive people with definite or probable tuberculous pericarditis at a secondary level hospital in the Northern Cape of South Africa.</P>
<P>All participants received standard treatment according to the South African National Tuberculosis Management Guidelines, that is weight-adjusted antituberculosis drugs and oral corticosteroids for 4 weeks. Participants also had pericardial "aspiration until dryness", and antiretroviral therapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-25 23:24:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention</B>
</P>
<UL>
<LI>Colchicine 1.0 mg per day for 6 weeks.</LI>
</UL>
<P>
<B>Comparison</B>
</P>
<UL>
<LI>Placebo for 6 weeks.</LI>
</UL>
<P>Participants were followed up with serial echocardiography for 16 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-25 23:24:27 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome</B>
</P>
<UL>
<LI>Constrictive pericarditis.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-04-21 23:15:50 +0100" MODIFIED_BY="[Empty name]">
<P>Study location: Kimberley, South Africa.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-27 20:15:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mayosi-2014">
<CHAR_METHODS MODIFIED="2017-06-25 23:24:13 +0100" MODIFIED_BY="[Empty name]">
<P>Computer-generated randomization list</P>
<P>Double-blind placebo-controlled 2 × 2 factorial study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-25 23:24:13 +0100" MODIFIED_BY="[Empty name]">
<P>1400 participants (two-thirds HIV-positive) 18 years of age or older, with a pericardial effusion confirmed by echocardiography, evidence of definite or probable tuberculous pericarditis, and had begun antituberculous treatment less than 1 week before enrolment.</P>
<P>&#8220;Trial participants received antimicrobial treatment for tuberculosis and antiretroviral treatment for HIV according to World Health Organization (WHO) guidelines; management during the course of the trial was revised as recommended treatment practices evolved&#8221;.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-25 23:24:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention 1</B>
</P>
<UL>
<LI>Prednisolone for 6 weeks at a dose of 120 mg per day in the first week, 90 mg per day in the second week, 60 mg per day in the 3rd week, 30 mg per day in the 4th week, 15 mg per day in the 5th week, and 5 mg per day in the 6th week.</LI>
</UL>
<P>
<B>Control 1</B>
</P>
<UL>
<LI>Identical placebo for 6 weeks at a dose of 120 mg per day in the 1st week, 90 mg per day in the 2nd week, 60 mg per day in the 3rd week, 30 mg per day in the 4th week, 15 mg per day in the 5th week, and 5 mg per day in the 6th week.</LI>
</UL>
<P>
<B>Intervention 2</B>
</P>
<UL>
<LI>
<I>M. indicus pranii</I> preparation (CADI-Mw injection, Cadila Pharmaceuticals) in 5 doses: at the time of enrolment and at 2 weeks, 4 weeks, 6 weeks, and 3 months. The 1st dose was given as 2 injections of 0.1 mL (containing 0.5 × 10<SUP>9</SUP> organisms) in each deltoid region of the upper arm; the 4 subsequent doses were given as a single injection of 0.1 mL.</LI>
</UL>
<P>
<B>Control 2</B>
</P>
<UL>
<LI>Identical placebo in 5 doses: at the time of enrolment and at 2 weeks, 4 weeks, 6 weeks, and 3 months. The 1st dose was given as 2 injections of 0.1 mL in each deltoid region of the upper arm; the 4 subsequent doses were given as a single injection of 0.1 mL.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-25 23:24:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome</B>
</P>
<UL>
<LI>Composite of death or 1st occurrence of cardiac tamponade requiring pericardiocentesis or constrictive pericarditis.</LI>
</UL>
<P>
<B>Secondary outcomes</B>
</P>
<UL>
<LI>Individual components of the primary outcome.</LI>
<LI>Hospitalization.</LI>
</UL>
<P>
<B>Safety outcomes</B>
</P>
<UL>
<LI>Opportunistic infections.</LI>
<LI>Cancer.</LI>
<LI>CD4+ T-lymphocyte cell count (measure of immunosuppression) and immune reconstitution inflammatory syndrome (in HIV-positive).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-27 20:15:06 +0100" MODIFIED_BY="[Empty name]">
<P>Study location: multiple sites in South Africa, Mozambique, Malawi, Uganda, Sierra Leone, Zimbabwe, Kenya, and Nigeria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-07-05 15:02:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reuter-2006">
<CHAR_METHODS MODIFIED="2017-06-25 23:25:29 +0100" MODIFIED_BY="[Empty name]">
<P>Computer-generated randomization list</P>
<P>Double-blind placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-07-05 15:02:34 +0100" MODIFIED_BY="[Empty name]">
<P>57 participants, aged 17 to 66 years, with large pericardial effusions on echocardiography, pericardial aspirate with protein content &gt; 30 g/L, and pericardial fluid adenosine deaminase (ADA) activity &gt; 35 U/L; 23 females and 34 males; 40 had microbiological or histological evidence of TB or both, and 17 patients were diagnosed by clinical and supportive laboratory data. 21 (37.0%) were HIV-positive.</P>
<P>"A standard short-course anti-tuberculous regimen was initiated according to national guidelines, namely a combination of rifampicin, isoniazid, pyrazinamide and ethambutol for two months, followed by rifampicin and isoniazid for a further four months...Patients were discharged on anti-tuberculous therapy and pyridoxine, with or without adjunctive prednisone. HIV-positive patients also received daily oral cotrimoxazole; due to the prevailing national policy at the time of this study, none of these patients received antiretroviral therapy".</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-25 23:25:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention 1</B>
</P>
<UL>
<LI>200 mg (5 mL) intrapericardial triamcinolone hexacetonide. Triamcinolone was injected directly into the pericardium just prior to the removal of the indwelling catheter. Due to limited resources, an oral placebo was not used in conjunction with the intrapericardial triamcinolone. 17 participants were in this arm, 6 (35%) were HIV-positive.</LI>
</UL>
<P>
<B>Intervention 2</B>
</P>
<UL>
<LI>Oral prednisone plus intrapericardial placebo (5 mL 0.9% saline solution). Oral prednisone was started at 60 mg/day for 4 weeks, followed by 30 mg/day for 4 weeks, 15 mg/day for 2 weeks and 5 mg/day for 1 week. There were 16 participants in this arm, 9 (56%) were HIV-positive.</LI>
</UL>
<P>
<B>Control</B>
</P>
<UL>
<LI>Placebo (5 mL intrapericardial 0.9% saline). 24 participants were included in this arm, and 6 (25%) were HIV-positive.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-25 23:25:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome</B>
</P>
<UL>
<LI>All-cause mortality.</LI>
</UL>
<P>
<B>Secondary outcomes</B>
</P>
<UL>
<LI>Death attributed to pericarditis.</LI>
<LI>Disability related to pericardial disease at 1 year (defined as a history of restricted physical activity using New York Heart Association functional classification.</LI>
<LI>Effusive constriction.</LI>
<LI>Fibrous constrictive pericarditis requiring pericardiectomy.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-06-25 23:25:49 +0100" MODIFIED_BY="[Empty name]">
<P>Study location: Cape Town, South Africa.</P>
<P>We excluded data from the intrapericardial triamcinolone arm from this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-25 23:26:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schrire-1959">
<CHAR_METHODS MODIFIED="2017-06-25 23:26:02 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation of 28 participants to adjuvant steroids or no steroids</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-25 23:26:02 +0100" MODIFIED_BY="[Empty name]">
<P>28 participants who were on antituberculous chemotherapy for suspected tuberculous pericarditis. The trial authors did not provide the characteristics of the included participants, and did not specify the antituberculous drugs used.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-25 23:26:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention</B>
</P>
<UL>
<LI>Cortisone with a loading dose of 300 mg and maintenance dose of 100 mg daily for several weeks was prescribed for 14 participants. At a later date, prednisolone 60 mg/day with a maintenance dose of 20 mg was substituted.</LI>
</UL>
<P>
<B>Control</B>
</P>
<UL>
<LI>No corticosteroids.</LI>
</UL>
<P>The trial authors did not specify the length of follow-up.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 15:51:18 +0000" MODIFIED_BY="[Empty name]">
<P>Constriction requiring pericardiectomy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-05-20 19:21:39 +0100" MODIFIED_BY="[Empty name]">
<P>Study location: Cape Town, South Africa</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-28 05:23:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strang-2004a">
<CHAR_METHODS MODIFIED="2017-06-25 23:26:51 +0100" MODIFIED_BY="[Empty name]">
<P>Central randomization</P>
<P>Double blind placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-27 20:16:14 +0100" MODIFIED_BY="[Empty name]">
<P>143 participants with suspected tuberculous constrictive pericarditis aged 5 years and older. The participants in the treatment and control groups were well-matched in terms of clinical characteristics and completion of antituberculous chemotherapy.</P>
<P>"Those consenting to take part were all prescribed the same 6-month standard antituberculosis regimen of streptomycin, isoniazid, rifampicin, and pyrazinamide daily for 14 weeks as an in-patient, followed by isoniazid and rifampicin daily up to 6 months."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-27 20:16:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention</B>
</P>
<UL>
<LI>Prednisolone for the first 11 weeks of antituberculous chemotherapy. The dose for children aged 5 to 9 years was 30 mg daily for weeks 1 to 4; 15 mg daily for weeks 5 to 8; 7.5 mg daily for weeks 9 to 10; and 2.5 mg daily for week 11. Regarding children aged 10 to 14 years, the dose was 45 mg for weeks 1 to 4; 22.5 mg for weeks 5 to 8; 7.5 mg for weeks 9 to 10; and 2.5 mg for week 11. The dose for adults was 60 mg for the first 4 weeks; 30 mg for weeks 5 to 8; 15 mg for weeks 9 to 10; and 5 mg for week 1.</LI>
</UL>
<P>
<B>Control</B>
</P>
<UL>
<LI>Matching placebo.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-28 05:23:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Death.</LI>
<LI>Death from pericarditis.</LI>
<LI>Favourable clinical status at 24 months.</LI>
<LI>Pericardiectomy.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-04-08 06:03:46 +0100" MODIFIED_BY="[Empty name]">
<P>Study location: Umtata, South Africa</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2017-06-28 05:23:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strang-2004b">
<CHAR_METHODS MODIFIED="2017-06-25 23:27:28 +0100" MODIFIED_BY="[Empty name]">
<P>Central randomization</P>
<P>Double blind placebo-controlled study</P>
<P>Factorial design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-28 05:23:33 +0100" MODIFIED_BY="[Empty name]">
<P>240 participants aged 5 years or more diagnosed as having active tuberculous pericardial effusion. The participants in the treatment and control groups were well-matched in terms of their clinical characteristics and completion of antituberculous chemotherapy.</P>
<P>"Those consenting to take part were all prescribed the same 6-month standard antituberculosis regimen of streptomycin, isoniazid, rifampicin, and pyrazinamide daily for 14 weeks as an in-patient, followed by isoniazid and rifampicin daily up to 6 months."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-28 05:23:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention 1</B>
</P>
<UL>
<LI>Complete open surgical drainage on admission.</LI>
</UL>
<P>
<B>Control 1</B>
</P>
<UL>
<LI>No open drainage.</LI>
</UL>
<P>
<B>Intervention 2</B>
</P>
<UL>
<LI>Prednisolone for the first 11 weeks of antituberculous chemotherapy. The dose for children aged 5 to 9 years was 30 mg daily for weeks 1 to 4; 15 mg daily for weeks 5 to 8; 7.5 mg daily for weeks 9 to 10; and 2.5 mg daily for week 11. Regarding children aged 10 to 14 years, the dose was 45 mg for weeks 1 to 4; 22.5 mg for weeks 5 to 8; 7.5 mg for weeks 9 to 10; and 2.5 mg for week 11. The dose for adults was 60 mg for the first 4 weeks; 30 mg for weeks 5 to 8; 15 mg for weeks 9 to 10; and 5 mg for week 1.</LI>
</UL>
<P>
<B>Control 2</B>
</P>
<UL>
<LI>Matching placebo.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-28 05:23:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Death.</LI>
<LI>Death from pericarditis.</LI>
<LI>Favourable clinical status at 24 months.</LI>
<LI>Tamponade requiring pericardiocentesis.</LI>
<LI>Constriction.</LI>
<LI>Pericardiectomy.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-04-08 06:03:18 +0100" MODIFIED_BY="[Empty name]">
<P>Study location: Umtata, South Africa</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-06-25 23:29:21 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-06-25 23:29:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wiysonge-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-25 23:29:21 +0100" MODIFIED_BY="[Empty name]">
<P>Although this study is indexed in electronic databases as a controlled trial, it is actually a cross-sectional study of the contemporary use of adjunctive steroids by physicians treating patients with tuberculous pericarditis. We thus excluded it from this review due to ineligible study design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2017-06-25 23:29:31 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2017-06-25 23:29:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cui-2005">
<CHAR_METHODS MODIFIED="2017-06-25 23:29:31 +0100" MODIFIED_BY="[Empty name]">
<P>Consecutively recruited participants were "randomly" assigned to intervention or control arms, but no further details about random sequence generation and allocation concealment are not provided in the abstract. The length of following-up varied from 8 to 120 months (mean 56.8 ± 29.0 months).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-25 23:29:31 +0100" MODIFIED_BY="[Empty name]">
<P>Ninety-four participants with infectious exudative pericarditis (34 with purulent pericarditis and 60 with tuberculous pericarditis); disease course less than 1 month; 44 males and 50 females; age 9 to 66 years (mean 45.4 ± 14.7 years); consecutively enrolled between 1993 to 2002 in China. The hospital and city are not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-25 23:29:31 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention arm: intrapericardial urokinase along with conventional treatment in intervention arm, or conventional treatment alone (including pericardiocentesis and drainage) in the control arm. The dosage of urokinase ranged from 200,000 to 600,000 U (mean 320,000 ± 70,000 U).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-25 23:29:31 +0100" MODIFIED_BY="[Empty name]">
<P>Pericardial constriction, as detected by pericardiography with sterilized air and diatrizoate meglumine as contrast media (in the short-tem) and telephonic survey and echocardiographic examination (in the long-term).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-02 18:33:42 +0100" MODIFIED_BY="[Empty name]">
<P>Study published in Chinese. Only the abstract is currently available in English.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-06-28 05:23:33 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2017-06-28 05:23:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT02673879">
<CHAR_STUDY_NAME MODIFIED="2017-04-21 22:37:52 +0100" MODIFIED_BY="[Empty name]">
<P>The Second Investigation of the Management of Pericarditis (IMPI-2) Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-06-25 23:30:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design</B>: randomized trial</P>
<P>
<B>Intervention model</B>: parallel assignment</P>
<P>
<B>Blinding</B>: single blind (outcomes assessor)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-06-25 23:30:25 +0100" MODIFIED_BY="[Empty name]">
<P>The study plans to enrol 2176 participants.</P>
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Age &#8805; 18 years of age.</LI>
<LI>Confirmed large pericardial effusion on echocardiography (that is, echo free space &#8805; 1 cm anterior to the right ventricle of the heart in diastole).</LI>
<LI>Willingness to participate for the full duration of the trial (that is, 12 months).</LI>
<LI>Provision of written informed consent.</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Age &lt; 18 years.</LI>
<LI>Uraemic pericarditis (that is, urea &gt; 21.4 mmol/L).</LI>
<LI>Thrombocytopenia (that is, &lt; 100,000 platelets/µL).</LI>
<LI>Presence of a contraindication to the administration of a fibrinolytic agent (major haemorrhage or major trauma; coincidental stroke; major surgery in the previous 5 days; blood pressure &gt; 200/100 mmHg).</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-06-25 23:30:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Intervention</B>: complete percutaneous pericardial drainage facilitated by intrapericardial alteplase (recombinant human tissue-type plasminogen activator).</P>
<P>
<B>Comparison</B>: conventional pericardiocentesis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-06-25 23:30:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes</B>
</P>
<UL>
<LI>Composite outcome of cardiac tamponade requiring pericardiocentesis or constrictive pericarditis.</LI>
</UL>
<P>
<B>Secondary outcomes</B>
</P>
<UL>
<LI>Major bleeding.</LI>
<LI>Clinically relevant non-major bleeding.</LI>
<LI>Any bleeding.</LI>
<LI>Any other form of bleeding that is not covered by safety outcomes 1-3.</LI>
<LI>Other adverse events.</LI>
<LI>Any other adverse events.</LI>
<LI>Persistent pericardial effusion without cardiac tamponade.</LI>
<LI>Recurrent pericardial effusion without cardiac tamponade.</LI>
<LI>Hospitalization for any cause; and death from any cause.</LI>
<LI>Cardiac tamponade requiring pericardiocentesis.</LI>
<LI>Constrictive pericarditis.</LI>
<LI>Death from any cause.</LI>
<LI>Proportion with proven tuberculosis.</LI>
<LI>Time to diagnosis of proven tuberculosis.</LI>
<LI>Proportion with proven tuberculosis on novel tests who are not put on treatment.</LI>
<LI>Diagnostic accuracy of novel tests of tuberculosis.</LI>
<LI>Drug-resistant tuberculosis.</LI>
<LI>Specific diagnosis of tuberculous pericarditis.</LI>
<LI>Time to diagnosis of specific pericardial disease.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2017-06-28 05:23:33 +0100" MODIFIED_BY="[Empty name]">
<P>The study started in February 2016, with the planned completion date as January 2019.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-06-25 23:30:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Principal investigator</B>: Professor Bongani M, Mayosi, University of Cape Town, Cape Town, South Africa.</P>
<P>
<B>Contacts:</B>
</P>
<UL>
<LI>Shaheen Pandie: Phone +27823199030; Email: <A HREF="mailto:s.pandie%40uct.ac.za?subject=NCT02673879,%20HREC%20REF%20No.%20370/2015,%20IMPI%202%20-%20A%20Trial%20of%20Intrapericardial%20Alteplase%20in%20Large%20Pericardial%20Effusion">s.pandie@uct.ac.za</A>
</LI>
<LI>Veronica Francis: Phone +27832449895; Email: <A HREF="mailto:veronica.francis%40uct.ac.za?subject=NCT02673879,%20HREC%20REF%20No.%20370/2015,%20IMPI%202%20-%20A%20Trial%20of%20Intrapericardial%20Alteplase%20in%20Large%20Pericardial%20Effusion">veronica.francis@uct.ac.za</A>
</LI>
</UL>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2017-04-21 21:59:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Sponsor:</B> University of Cape Town, South Africa.</P>
<P>
<B>Collaborators: </B>Walter Sisulu University, South Africa; Population Health Research Institute, Canada</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-07-05 15:24:42 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-06-25 23:34:54 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:24:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hakim-2000">
<DESCRIPTION>
<P>"Randomisation was achieved by the use of a computer generated randomisation list".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:21:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liebenberg-2016">
<DESCRIPTION>
<P>The mention of an internet-based computer system implies use of a computer-generated randomization sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:24:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mayosi-2014">
<DESCRIPTION>
<P>Computer-generated randomization list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-14 18:04:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reuter-2006">
<DESCRIPTION>
<P>Participants were "randomly assigned as per a predetermined randomisation schedule for 100 patients on a 3:3:4 basis. Numbers were drawn from a hat, stored on a list on a computer and provided to the treating physician with the assigned treatment by a non-clinical administrator." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schrire-1959">
<DESCRIPTION>
<P>The trial authors performed randomization by alternation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:27:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strang-2004a">
<DESCRIPTION>
<P>The trial authors used a random number list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:34:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strang-2004b">
<DESCRIPTION>
<P>The trial used a random number list to perform random sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-06-25 23:34:54 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-02 18:33:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hakim-2000">
<DESCRIPTION>
<P>"Prednisolone/placebo packages were prepared according to the randomisation list, but labelled with the study number only. A package consisted of six well labelled bottles each containing the number of tablets required in each of the six weeks of the intervention. Eligible patients were given a drug package consecutively working down the randomisation list."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-21 23:24:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liebenberg-2016">
<DESCRIPTION>
<P>Participants "were randomised to an intervention and control group using a web-based computer system that ensured assignment concealment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:24:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mayosi-2014">
<DESCRIPTION>
<P>Central allocation, stratified by centre, with random block sizes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-02 18:33:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reuter-2006">
<DESCRIPTION>
<P>An unblinded, independent physician administered one of the three randomly assigned treatment options.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schrire-1959">
<DESCRIPTION>
<P>There was no allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:27:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strang-2004a">
<DESCRIPTION>
<P>The trial authors used central randomization.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:34:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strang-2004b">
<DESCRIPTION>
<P>The trial authors performed central randomization.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-04-07 00:27:21 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-07-05 15:24:42 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-02 18:33:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hakim-2000">
<DESCRIPTION>
<P>"Clinicians and patients were blinded to the identity of the tablets. A randomisation code list was kept sealed and was released at the end of the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-06-25 23:21:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liebenberg-2016">
<DESCRIPTION>
<P>The study authors reported that "Upon completion of the research period, the blinding was unveiled and data were presented for statistical analysis", but did not provide further details of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-05-02 18:33:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mayosi-2014">
<DESCRIPTION>
<P>Both prednisolone and <I>M. indicus pranii</I> preparation had identical placebos.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-28 07:45:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reuter-2006">
<DESCRIPTION>
<P>"The randomisation code remained concealed and was not revealed to the investigators or the study subjects until completion of the study." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-06-25 23:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schrire-1959">
<DESCRIPTION>
<P>The trial did not perform any blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-06-25 23:27:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strang-2004a">
<DESCRIPTION>
<P>Particianpts and care providers were blinded to treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-07-05 15:24:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strang-2004b">
<DESCRIPTION>
<P>The participants and investigators were blinded to the steroid component, but not to the surgical drainage component.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-06-25 23:34:54 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-25 23:24:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hakim-2000">
<DESCRIPTION>
<P>Two cardiologists with extensive experience of echocardiography in this setting performed all examinations. "Clinicians and patients were blinded to the identity of the tablets. A randomisation code list was kept sealed and was released at the end of the study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-25 23:21:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liebenberg-2016">
<DESCRIPTION>
<P>The study reported that blinding was unveiled only after completion of the follow-up period, when presenting data to the statistician.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-25 23:24:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mayosi-2014">
<DESCRIPTION>
<P>A committee of clinicians blinded to treatment allocation (the Outcomes Adjudication Committee) adjudicated all primary and secondary outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-05-20 19:21:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reuter-2006">
<DESCRIPTION>
<P>The study states that outcomes were assessed using a combination of clinical and echocardiographic features, but there is no mention of blinding of outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-25 23:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schrire-1959">
<DESCRIPTION>
<P>There was no evidence of blinding of outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-25 23:27:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strang-2004a">
<DESCRIPTION>
<P>Investigators, including outcome assessors, were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-06-25 23:34:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strang-2004b">
<DESCRIPTION>
<P>"For patients who died, information was obtained on cause of death from hospital records, relatives, or other contacts. All the deaths were reviewed by an independent assessor without knowledge of the treatment group, and where possible, he classified the cause."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-06-28 05:23:33 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-25 23:24:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hakim-2000">
<DESCRIPTION>
<P>Follow-up data was available on all 58 enrolled participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-25 23:21:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liebenberg-2016">
<DESCRIPTION>
<P>In this study, 5/33 (15.15%) participants were lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-25 23:24:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mayosi-2014">
<DESCRIPTION>
<P>Participants were analysed in groups to which they were randomized, regardless of how much of the intended intervention they actually received. Primary outcome data were known for 1371 of 1400 (97.9%) participants in the prednisolone-placebo comparison; with no significant differences between prednisolone (688/706;. 97.5%) and placebo (683/694; 98.4%) arms. For the <I>M. indicus pranii</I> - placebo comparison, primary outcome data were available for 1223 of 1250 participants (97.8%); with no significant differences between <I>M. indicus pranii</I> (611/625; 97.8%) and placebo (612/625; 97.9%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-28 05:23:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Reuter-2006">
<DESCRIPTION>
<P>Nine (16.0%) participants were lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-25 23:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schrire-1959">
<DESCRIPTION>
<P>The trial authors did not adequately report losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-25 23:27:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strang-2004a">
<DESCRIPTION>
<P>During 10 years of follow-up, 1 participant (1.4%) was lost to follow-up in the prednisolone group and 2 participants (2.7%) in the placebo group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-06-25 23:34:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strang-2004b">
<DESCRIPTION>
<P>5/117 (4.3%) participants were lost to follow-up in the prednisolone group compared to 7/119 (5.9%) in the placebo group.</P>
<P>2/64 (3.1%) participants were lost to follow-up in the drainage group compared to 3/58 (5.2%) in the no drainage group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-06-25 23:34:54 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:24:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hakim-2000">
<DESCRIPTION>
<P>The study protocol was not available and there is no earlier methods paper listing the prespecified outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-04-21 23:16:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liebenberg-2016">
<DESCRIPTION>
<P>We do not have access to the study protocol and are unable to comment on whether there was selective reporting of outcomes in this study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:24:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mayosi-2014">
<DESCRIPTION>
<P>The study authors reported the outcomes planned for in the prospective trial registration (ClinicalTrials.gov registration number NCT100810849) and published protocol in the trial report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-05-20 19:21:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reuter-2006">
<DESCRIPTION>
<P>We do not have access to the study protocol and are unable to comment on whether there was selective reporting of outcomes in this study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schrire-1959">
<DESCRIPTION>
<P>The study protocol was not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:27:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strang-2004a">
<DESCRIPTION>
<P>There was no study protocol available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:34:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strang-2004b">
<DESCRIPTION>
<P>There was no study protocol available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-06-25 23:34:54 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:24:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hakim-2000">
<DESCRIPTION>
<P>There is no evidence that the study had any additional biases to the ones mentioned above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:21:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liebenberg-2016">
<DESCRIPTION>
<P>There was no evidence of other sources of bias in the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:24:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mayosi-2014">
<DESCRIPTION>
<P>There was no evidence of other biases in the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-02 18:33:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reuter-2006">
<DESCRIPTION>
<P>No evidence of other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schrire-1959">
<DESCRIPTION>
<P>There was no evidence of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:27:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strang-2004a">
<DESCRIPTION>
<P>There was no evidence of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-06-25 23:34:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Strang-2004b">
<DESCRIPTION>
<P>There was no evidence of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-07-31 01:45:58 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-07-05 15:08:32 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2017-06-27 20:25:38 +0100" MODIFIED_BY="[Empty name]">Corticosteroids for tuberculous pericarditis in HIV-negative people</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Population:</B> HIV-negative people with tuberculous pericarditis<BR/>
<B>Settings:</B> any setting<BR/>
<B>Intervention:</B> corticosteroids</P>
<P>
<B>Comaprison:</B> placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Number of participants<BR/>(trials)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Certainty of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Comments</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Steroids</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Death from all causes</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>22 per 100</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>18 per 100<BR/>(13 to 24)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>RR 0.80<BR/>(0.59 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>660<BR/>(4 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low<SUP>1,2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Steroids may reduce the risk of deaths from all causes among HIV-negative people.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Death from pericarditis<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>8 per 100</P>
</TD>
<TD VALIGN="TOP">
<P>3 per 100<BR/>(1 to 6)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.39<BR/>(0.19 to 0.80)</P>
</TD>
<TD VALIGN="TOP">
<P>660<BR/>(4 trials)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>moderate<SUP>2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Steroids probably reduce the risk of deaths from pericarditis among HIV-negative people.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Constrictive pericarditis<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>10 per 100</P>
</TD>
<TD VALIGN="TOP">
<P>7 per 100<BR/>(3 to 15)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.72<BR/>(0.34 to 1.55)</P>
</TD>
<TD VALIGN="TOP">
<P>281<BR/>(2 trials)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>very low<SUP>2,3,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>It is uncertain whether steroids have an effect on the risk of constriction among HIV-negative people.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Repeat pericardiocentesis<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>40 per 100</P>
</TD>
<TD VALIGN="TOP">
<P>34 per 100<BR/>(28 to 41)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.85<BR/>(0.70 to 1.04)</P>
</TD>
<TD VALIGN="TOP">
<P>492<BR/>(2 trials)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low<SUP>1,4</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Steroids may reduce the risk of repeat drainage of the pericardium among HIV-negative people.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cancer<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 per 100</P>
</TD>
<TD VALIGN="TOP">
<P>1 per 100<BR/>(0 to 12)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.85<BR/>(0.05 to 13.80)</P>
</TD>
<TD VALIGN="TOP">
<P>256<BR/>(1 trial)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>very low<SUP>3,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>It is uncertain whether steroids have an effect on the risk of cancer among HIV-negative people.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Abbreviations:</B> CI: confidence interval; RR: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High certainty:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate certainty:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low certainty:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low certainty:</B> we are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>We downgraded by 1 for imprecision: the CI ranges from a large clinical benefit to a small increase in harm.<BR/>
<SUP>2</SUP>We downgraded by 1 for study limitations: one trial was at high risk of bias.<BR/>
<SUP>3</SUP>We downgraded by 2 for imprecision: the CI ranges from clinically important benefits to a large increase in harm.<BR/>
<SUP>4</SUP>We downgraded by 1 for selective reporting: data were only reported by 2 of the 4 trials that recruited HIV-negative people.<BR/>
<SUP>5</SUP>We downgraded by 1 for selective reporting: data were only reported by 1 of the 4 trials that recruited HIV-negative people.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2017-07-31 01:45:58 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2017-07-05 15:08:46 +0100" MODIFIED_BY="[Empty name]">Corticosteroids for tuberculous pericarditis in HIV-positive people</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Population:</B> HIV-positive people with tuberculous pericarditis. Most patients (80%) not on antiretroviral drugs<BR/>
<B>Settings:</B> any setting<BR/>
<B>Intervention:</B> corticosteroids</P>
<P>
<B>Comparison:</B> placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>Number of participants<BR/>(trials)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Certainty</B> of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Comments</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Corticosteroids</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Death from all causes<BR/>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>17 per 100</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>15 per 100<BR/>(6 to 40)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>RR 0.91<BR/>(0.34 to 2.42)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>575<BR/>(3 trials)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>very low<SUP>1,2</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>It is uncertain whether steroids have an effect on the risk of deaths from all causes among people living with HIV.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Death from pericarditis<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>4 per 100</P>
</TD>
<TD VALIGN="TOP">
<P>4 per 100<BR/>(2 to 10)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.07<BR/>(0.46 to 2.54)</P>
</TD>
<TD VALIGN="TOP">
<P>517<BR/>(2 trials)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>very low<SUP>1,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>It is uncertain whether steroids have an effect on the risk of deaths from pericarditis among people living with HIV.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Constrictive pericarditis<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>6 per 100</P>
</TD>
<TD VALIGN="TOP">
<P>4 per 100<BR/>(2 to 7)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.55<BR/>(0.26 to 1.16)</P>
</TD>
<TD VALIGN="TOP">
<P>575<BR/>(3 trials)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low<SUP>1</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Steroids may reduce the risk of developing constriction among people living with HIV.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Repeat pericardiocentesis<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>60 per 100</P>
</TD>
<TD VALIGN="TOP">
<P>61 per 100<BR/>(53 to 71)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.02 <BR/>(0.89 to 1.18)</P>
</TD>
<TD VALIGN="TOP">
<P>517<BR/>(2 trials)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>low<SUP>3,5</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>Steroids may have little or no effect on the risk of repeat pericardiocentesis among people living with HIV.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cancer<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>1 per 100</P>
</TD>
<TD VALIGN="TOP">
<P>1 per 100<BR/>(0 to 8)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 1.62<BR/>(0.27 to 9.77)</P>
</TD>
<TD VALIGN="TOP">
<P>502<BR/>(1 trial)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>very low<SUP>1,3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>It is uncertain whether steroids have an effect on the risk of cancer among people living with HIV.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Abbreviations: </B>CI: confidence interval; RR: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High certainty:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate certainty:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low certainty:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low certainty:</B> we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>We downgraded by 2 for imprecision: the CI ranges from substantial clinical benefits to substantial harm.<BR/>
<SUP>2</SUP>We downgraded by 1 for unexplained heterogeneity (Chi² = 3.82, df = 1 (P = 0.05); I² statistic = 74%).<BR/>
<SUP>3</SUP>We downgraded by 1 for selective reporting: only 2 of the 3 studies that recruited HIV-positive people reported data.<BR/>
<SUP>4</SUP>We downgraded by 1 for study limitations: 1 study had a high risk of bias.<BR/>
<SUP>5</SUP>We downgraded by 1 for imprecision: the CI ranges from a small beneficial effect to clinically important harms.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2017-07-06 10:06:23 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2017-07-06 10:06:23 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2017-06-27 20:43:09 +0100" MODIFIED_BY="[Empty name]">Key characteristics of the corticosteroid trials</TITLE>
<TABLE COLS="9" ROWS="8">
<TR>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Trial</B>
</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Location</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="5" VALIGN="BOTTOM">
<P>
<B>Participants</B>
</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Intervention</B>
</P>
</TH>
<TH ROWSPAN="2" VALIGN="BOTTOM">
<P>
<B>Outcomes</B>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Sample size</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Age (years)</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>HIV-positive</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>ART</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Definite TB</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>South Africa</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>28 people with pericardial effusion</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adults</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>None</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cortisone (or prednisolone) for several weeks versus no corticosteroids<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pericardiectomy</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Zimbabwe</P>
</TD>
<TD VALIGN="TOP">
<P>58 people with pericardial effusion</P>
</TD>
<TD VALIGN="TOP">
<P>18 to 55</P>
</TD>
<TD VALIGN="TOP">
<P>100%</P>
</TD>
<TD VALIGN="TOP">
<P>0%</P>
</TD>
<TD VALIGN="TOP">
<P>38%</P>
</TD>
<TD VALIGN="TOP">
<P>Prednisolone for 6 weeks versus placebo<SUP>3</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>All-cause deaths; constrictive pericarditis.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>South Africa</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>143 with constrictive pericarditis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8805; 5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Assume</P>
<P>none</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Prednisolone first 11 weeks versus placebo<SUP>2</SUP>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>All-cause deaths; deaths from pericarditis; pericardiectomy.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>South Africa</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>240 people with pericardial effusion</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8805; 5</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Assume</P>
<P>none</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>N/A</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(1) Prednisolone for 11 weeks versus placebo</P>
<P>(2) Open surgical drainage versus no drainage</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>All-cause deaths; deaths from pericarditis; repeat pericardiocentesis; pericardiectomy.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>South Africa</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 people with pericardial effusion</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17 to 66</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>38%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Prednisone versus no prednisone (5 mL intrapericardial 0.9% saline)<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Repeat pericardiocentesis; pericardiectomy; constrictive pericarditis; infection.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Kenya, Malawi, Mozambique, Nigeria, Uganda, Sierra Leone, South Africa, and Zimbabwe</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1440 with pericardial effusion (83%) or constriction (17%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8805; 18</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>67%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>22%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Prednisolone for 6 weeks with or without <I>M. indicus pranii</I> versus placebo<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>All-cause deaths; deaths from pericarditis; constrictive pericarditis; hospitalization; infection; cancer.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Abbreviations: ART: proportion of participants on antiretroviral therapy; HIV: human immunodeficiency virus; TB: tuberculosis.</P>
<P>
<SUP>1</SUP>In the <LINK REF="STD-Schrire-1959" TYPE="STUDY">Schrire 1959</LINK> study, corticosteroid dose was given at a loading dose of 300 mg daily followed by a maintenance dose of 100 mg daily. At a later date, cortisone was substituted by prednisolone with a loading dose of 60 mg daily and a maintenance dose of 20 mg daily.<BR/>
<SUP>2</SUP>In the <LINK REF="STD-Strang-2004a" TYPE="STUDY">Strang 2004a</LINK> and <LINK REF="STD-Strang-2004b" TYPE="STUDY">Strang 2004b</LINK> , the trial authors stratified prednisolone dosing by age: The dose for children aged 5 to 9 years was 30 mg daily for weeks 1 to 4; 15 mg daily for weeks 5 to 8; 7.5 mg daily for weeks 9 to 10; and 2.5 mg daily for week 11. For children 10 to 14 years, the dose was 45 mg for weeks 1 to 4; 22.5 mg for weeks 5 to 8; 7.5 mg for weeks 9 to 10; and 2.5 mg for week 11. The dose for adults was 60 mg for the first 4 weeks; 30 mg for weeks 5 to 8; 15 mg for weeks 9 to 10; and 5 mg for week 11.<BR/>
<SUP>3</SUP>In the <LINK REF="STD-Hakim-2000" TYPE="STUDY">Hakim 2000</LINK> study, the dose of prednisolone was 60 mg daily for the first week and was tapered thereafter by 10 mg every week.<BR/>
<SUP>4</SUP>In the <LINK REF="STD-Reuter-2006" TYPE="STUDY">Reuter 2006</LINK> study, the corticosteroid arm received oral prednisone plus intrapericardial placebo (5 mL 0.9% saline solution). Oral prednisone was started at 60 mg per day for 4 weeks, followed by 30 mg per day for 4 weeks, 15 mg per day for 2 weeks, and 5 mg per day for 1 week. This study had 3 arms. We did not include the third trial arm, which received intrapericardial triamcinolone, in this current review.<BR/>
<SUP>5</SUP>
<LINK REF="STD-Mayosi-2014" TYPE="STUDY">Mayosi 2014</LINK> used prednisolone for six weeks at a dose of 120 mg per day in the first week, 90 mg per day in the second week, 60 mg per day in the third week, 30 mg per day in the fourth week, 15 mg per day in the fifth week, and 5 mg per day in the sixth week.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2017-06-30 10:33:14 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2017-06-27 20:55:38 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Steroids versus placebo in HIV-negative people</NAME>
<DICH_OUTCOME CHI2="0.0014756553566166578" CI_END="1.086051646768368" CI_START="0.5908939733563886" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8010876186967378" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.03585047845096732" LOG_CI_START="-0.2284904394524069" LOG_EFFECT_SIZE="-0.0963199805007198" METHOD="MH" MODIFIED="2017-05-10 14:30:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9992624445165085" P_Q="1.0" P_Z="0.15319545772778229" Q="0.0" RANDOM="NO" SCALE="5.5" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="328" WEIGHT="100.0" Z="1.4283350021657872">
<NAME>Deaths from all causes</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.393389898829421" CI_START="0.45308361631318367" EFFECT_SIZE="0.7945578231292517" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="0.14407265785741072" LOG_CI_START="-0.34382164180100155" LOG_EFFECT_SIZE="-0.0998744919717954" MODIFIED="2016-05-13 13:48:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.28659152673508514" STUDY_ID="STD-Strang-2004a" TOTAL_1="70" TOTAL_2="73" VAR="0.08213470319634703" WEIGHT="28.285271170881263"/>
<DICH_DATA CI_END="1.251921902886614" CI_START="0.5129367051955075" EFFECT_SIZE="0.8013468013468014" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="33" LOG_CI_END="0.09757723765773353" LOG_CI_START="-0.28993622217913434" LOG_EFFECT_SIZE="-0.09617949226070038" MODIFIED="2016-05-13 13:48:00 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.22762732453073908" STUDY_ID="STD-Strang-2004b" TOTAL_1="117" TOTAL_2="119" VAR="0.05181419887302241" WEIGHT="45.01599439259908"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-05-17 15:55:26 +0100" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.0" STUDY_ID="STD-Reuter-2006" TOTAL_1="7" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4946545311712094" CI_START="0.43633279025884636" EFFECT_SIZE="0.8075684380032206" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.1745408230658235" LOG_CI_START="-0.36018214870611" LOG_EFFECT_SIZE="-0.09282066282014324" MODIFIED="2016-12-16 04:07:36 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.314098920540233" STUDY_ID="STD-Mayosi-2014" TOTAL_1="138" TOTAL_2="118" VAR="0.0986581318845396" WEIGHT="26.69873443651965"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.39421424129182636" CI_END="0.8008015587376662" CI_START="0.19066777895004322" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.39075190925220493" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.09647509018594513" LOG_CI_START="-0.7197226924102549" LOG_EFFECT_SIZE="-0.4080988912981" METHOD="MH" MODIFIED="2017-05-10 14:29:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8211027403608389" P_Q="1.0" P_Z="0.010265779434279889" Q="0.0" RANDOM="NO" SCALE="25.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="332" TOTAL_2="328" WEIGHT="100.0" Z="2.566745948866497">
<NAME>Deaths from pericarditis</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.672343348682202" CI_START="0.10930006073074314" EFFECT_SIZE="0.427536231884058" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.22332544722361036" LOG_CI_START="-0.961379596741795" LOG_EFFECT_SIZE="-0.3690270747590923" MODIFIED="2016-12-16 04:20:26 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.6959016072098263" STUDY_ID="STD-Mayosi-2014" TOTAL_1="138" TOTAL_2="118" VAR="0.4842790469172194" WEIGHT="25.661804303026518"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-05-17 15:55:11 +0100" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.0" STUDY_ID="STD-Reuter-2006" TOTAL_1="7" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1853890800999936" CI_START="0.057341458527504274" EFFECT_SIZE="0.26071428571428573" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.07386092216556084" LOG_CI_START="-1.2415312646090872" LOG_EFFECT_SIZE="-0.5838351712217633" MODIFIED="2016-05-13 13:47:51 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.7726678818077657" STUDY_ID="STD-Strang-2004a" TOTAL_1="70" TOTAL_2="73" VAR="0.5970156555772994" WEIGHT="31.070540394597156"/>
<DICH_DATA CI_END="1.2896337256449417" CI_START="0.16573355864206418" EFFECT_SIZE="0.46231546231546233" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.11046638199046459" LOG_CI_START="-0.7805895443421388" LOG_EFFECT_SIZE="-0.3350615811758371" MODIFIED="2016-05-13 13:47:51 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.523410661925743" STUDY_ID="STD-Strang-2004b" TOTAL_1="117" TOTAL_2="119" VAR="0.2739587210175445" WEIGHT="43.267655302376326"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5539358775106562" CI_START="0.33687704092243903" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7235228539576366" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.1914330938613892" LOG_CI_START="-0.4725285863488349" LOG_EFFECT_SIZE="-0.14054774624372282" METHOD="MH" MODIFIED="2016-12-25 01:21:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4066675164886251" Q="0.0" RANDOM="NO" SCALE="200.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="145" TOTAL_2="136" WEIGHT="100.0" Z="0.829772346677454">
<NAME>Constrictive pericarditis</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5539358775106562" CI_START="0.33687704092243903" EFFECT_SIZE="0.7235228539576366" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.1914330938613892" LOG_CI_START="-0.4725285863488349" LOG_EFFECT_SIZE="-0.14054774624372282" MODIFIED="2016-12-16 04:34:36 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.3900143776188093" STUDY_ID="STD-Mayosi-2014" TOTAL_1="138" TOTAL_2="118" VAR="0.15211121474938719" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-05-17 15:55:58 +0100" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.0" STUDY_ID="STD-Reuter-2006" TOTAL_1="7" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.269189135883122" CI_END="1.0432658193903044" CI_START="0.696163872657841" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8522229596991094" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="94" I2="84.04897382539833" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.018394978786888436" LOG_CI_START="-0.15728851812793174" LOG_EFFECT_SIZE="-0.06944676967052167" METHOD="MH" MODIFIED="2016-12-25 01:29:01 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.012285630288354277" P_Q="1.0" P_Z="0.1212550685411601" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="255" TOTAL_2="237" WEIGHT="100.00000000000001" Z="1.5495270732556654">
<NAME>Repeat pericardiocentesis</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2078805689470682" CI_START="0.8074076394666411" EFFECT_SIZE="0.987548479281486" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="71" LOG_CI_END="0.08202399487166259" LOG_CI_START="-0.09290714573260199" LOG_EFFECT_SIZE="-0.005441575430469714" MODIFIED="2016-12-16 04:39:05 +0000" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.10275541791405643" STUDY_ID="STD-Mayosi-2014" TOTAL_1="138" TOTAL_2="118" VAR="0.010558675910692388" WEIGHT="77.04616516461284"/>
<DICH_DATA CI_END="0.8235107137446246" CI_START="0.19234561613626663" EFFECT_SIZE="0.3979933110367893" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="23" LOG_CI_END="-0.08433074635469562" LOG_CI_START="-0.7159177075091021" LOG_EFFECT_SIZE="-0.40012422693189886" MODIFIED="2016-05-13 13:47:39 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.37099730738797815" STUDY_ID="STD-Strang-2004b" TOTAL_1="117" TOTAL_2="119" VAR="0.13763900208912996" WEIGHT="22.953834835387166"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="13.80401790136137" CI_START="0.05283540920703662" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8540145985401459" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="1.1400055138226817" LOG_CI_START="-1.2770749246431718" LOG_EFFECT_SIZE="-0.06853470541024514" METHOD="MH" MODIFIED="2017-03-25 08:05:53 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.9114998219512563" Q="0.0" RANDOM="NO" SCALE="96.86" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="118" WEIGHT="100.0" Z="0.11114694584215058">
<NAME>Cancer</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.804017901361375" CI_START="0.052835409207036596" EFFECT_SIZE="0.8540145985401459" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.140005513822682" LOG_CI_START="-1.277074924643172" LOG_EFFECT_SIZE="-0.06853470541024514" MODIFIED="2017-03-25 08:05:53 +0000" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="1.4198050142959777" STUDY_ID="STD-Mayosi-2014" TOTAL_1="138" TOTAL_2="118" VAR="2.0158462786200015" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6984715986787196" CI_START="0.5693026867194322" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9833333333333333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.23005828912760257" LOG_CI_START="-0.24465676661060154" LOG_EFFECT_SIZE="-0.0072992387414994656" METHOD="MH" MODIFIED="2017-06-27 20:55:38 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.951938223263298" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="118" WEIGHT="100.0" Z="0.060272977968442755">
<NAME>Hospitalization</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6984715986787196" CI_START="0.5693026867194322" EFFECT_SIZE="0.9833333333333333" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.23005828912760257" LOG_CI_START="-0.24465676661060154" LOG_EFFECT_SIZE="-0.0072992387414994656" MODIFIED="2016-12-16 08:28:37 +0000" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.2788499736180453" STUDY_ID="STD-Mayosi-2014" TOTAL_1="138" TOTAL_2="118" VAR="0.07775730778678457" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1021988712800406" CI_END="1.4146236088466395" CI_START="0.5836986073425394" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9086879719670887" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="33" I2="35.52960068047627" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.15064090180684164" LOG_CI_START="-0.233811342879958" LOG_EFFECT_SIZE="-0.0415852205365582" METHOD="MH" MODIFIED="2017-03-26 17:24:05 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.21201484642109547" P_Q="1.0" P_Z="0.6715595215787089" Q="0.0" RANDOM="NO" SCALE="500.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="208" TOTAL_2="224" WEIGHT="100.0" Z="0.4240086287294763">
<NAME>Pericardiectomy</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-05-14 16:17:29 +0100" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.0" STUDY_ID="STD-Reuter-2006" TOTAL_1="7" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="152.92664373195063" CI_START="0.5296657143798735" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1844831572089403" LOG_CI_START="-0.27599813833029024" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2016-05-13 13:48:08 +0100" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="1.4452988925785866" STUDY_ID="STD-Schrire-1959" TOTAL_1="14" TOTAL_2="14" VAR="2.0888888888888886" WEIGHT="1.5176698721753927"/>
<DICH_DATA CI_END="1.449096160127974" CI_START="0.502402836994497" EFFECT_SIZE="0.8532467532467533" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.16109720564184254" LOG_CI_START="-0.29894791686724465" LOG_EFFECT_SIZE="-0.06892535561270109" MODIFIED="2016-05-13 13:48:08 +0100" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.27023278222192143" STUDY_ID="STD-Strang-2004a" TOTAL_1="70" TOTAL_2="73" VAR="0.07302575658740042" WEIGHT="65.37654833986308"/>
<DICH_DATA CI_END="1.612187699922941" CI_START="0.25984675974398297" EFFECT_SIZE="0.6472416472416472" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.2074156034090641" LOG_CI_START="-0.5852826944042623" LOG_EFFECT_SIZE="-0.1889335454975991" MODIFIED="2016-05-13 13:48:08 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.46563490405540625" STUDY_ID="STD-Strang-2004b" TOTAL_1="117" TOTAL_2="119" VAR="0.2168158638746874" WEIGHT="33.10578178796153"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.689373394728808" CI_START="0.43720024292297255" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.710144927536232" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.8253854385515728" LOG_CI_START="-0.35931960541383257" LOG_EFFECT_SIZE="0.23303291656887007" METHOD="MH" MODIFIED="2016-12-25 01:51:00 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.4406745887893193" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="118" WEIGHT="100.0" Z="0.771054577700692">
<NAME>Opportunistic infections</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.689373394728808" CI_START="0.43720024292297255" EFFECT_SIZE="1.710144927536232" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8253854385515728" LOG_CI_START="-0.35931960541383257" LOG_EFFECT_SIZE="0.23303291656887007" MODIFIED="2016-12-16 08:33:56 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.6959016072098263" STUDY_ID="STD-Mayosi-2014" TOTAL_1="138" TOTAL_2="118" VAR="0.4842790469172194" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2017-06-30 10:32:55 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Steroids versus placebo in HIV-positive people</NAME>
<DICH_OUTCOME CHI2="3.821793849471855" CI_END="2.421170254658825" CI_START="0.344254835002105" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.912961974306476" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="49" I2="73.83427679810116" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.3840253297387434" LOG_CI_START="-0.4631199514341807" LOG_EFFECT_SIZE="-0.03954731084771864" METHOD="MH" MODIFIED="2017-05-10 14:29:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05059009468085196" P_Q="1.0" P_Z="0.8548026280541667" Q="0.0" RANDOM="YES" SCALE="5.5" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.37910394473565723" TOTALS="YES" TOTAL_1="280" TOTAL_2="295" WEIGHT="100.0" Z="0.1829941254931376">
<NAME>Deaths from all causes</NAME>
<GROUP_LABEL_1>Favours steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2826522698297491" CI_START="0.19490863258923902" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.10810893403442914" LOG_CI_START="-0.7101689253623915" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2016-05-13 13:58:25 +0100" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.4806604651504227" STUDY_ID="STD-Hakim-2000" TOTAL_1="29" TOTAL_2="29" VAR="0.2310344827586207" WEIGHT="40.58472594873328"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2017-03-26 07:52:45 +0100" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.0" STUDY_ID="STD-Reuter-2006" TOTAL_1="9" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.014906567918878" CI_START="0.941611699740458" EFFECT_SIZE="1.3774104683195592" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="39" LOG_CI_END="0.3042549125227676" LOG_CI_START="-0.026128153922955036" LOG_EFFECT_SIZE="0.13906337929990625" MODIFIED="2016-12-16 03:33:57 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.19406864865277212" STUDY_ID="STD-Mayosi-2014" TOTAL_1="242" TOTAL_2="260" VAR="0.03766264038991311" WEIGHT="59.41527405126672"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5360441195189156" CI_START="0.4551548337360697" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0743801652892562" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.4041568046895601" LOG_CI_START="-0.3418408407087868" LOG_EFFECT_SIZE="0.031157981990386677" METHOD="MH" MODIFIED="2017-05-10 14:28:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.8699491339630592" Q="0.0" RANDOM="NO" SCALE="25.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="251" TOTAL_2="266" WEIGHT="100.0" Z="0.16372309727464684">
<NAME>Deaths from pericarditis</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.536044119518916" CI_START="0.45515483373606963" EFFECT_SIZE="1.0743801652892562" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.40415680468956017" LOG_CI_START="-0.34184084070878684" LOG_EFFECT_SIZE="0.031157981990386677" MODIFIED="2016-12-16 04:15:31 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.43820270965488967" STUDY_ID="STD-Mayosi-2014" TOTAL_1="242" TOTAL_2="260" VAR="0.19202161474888751" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-05-14 17:06:38 +0100" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.0" STUDY_ID="STD-Reuter-2006" TOTAL_1="9" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3686620127383513" CI_END="1.1601302244841907" CI_START="0.2631511588198671" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5525301918944949" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.06450674146880152" LOG_CI_START="-0.5797947131710598" LOG_EFFECT_SIZE="-0.2576439858511291" METHOD="MH" MODIFIED="2017-01-07 13:03:06 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5044276246482517" P_Q="1.0" P_Z="0.11699665689896584" Q="0.0" RANDOM="NO" SCALE="200.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="280" TOTAL_2="295" WEIGHT="99.99999999999997" Z="1.5675051777861344">
<NAME>Constrictive pericarditis</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.627129539131202" CI_START="0.1508948925919286" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8213254597385299" LOG_CI_START="-0.8213254597385299" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-05-13 13:58:04 +0100" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.9649012813540154" STUDY_ID="STD-Hakim-2000" TOTAL_1="29" TOTAL_2="29" VAR="0.9310344827586208" WEIGHT="10.538144278975572"/>
<DICH_DATA CI_END="1.0481771940209756" CI_START="0.18671512299120815" EFFECT_SIZE="0.44239183276616434" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="17" LOG_CI_END="0.020434706197910348" LOG_CI_START="-0.7288205049451711" LOG_EFFECT_SIZE="-0.3541928993736304" MODIFIED="2016-12-16 04:32:32 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.4401162198985571" STUDY_ID="STD-Mayosi-2014" TOTAL_1="242" TOTAL_2="260" VAR="0.19370228701779507" WEIGHT="86.36240152132571"/>
<DICH_DATA CI_END="44.40378209183373" CI_START="0.09931586437568438" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6474199627195685" LOG_CI_START="-1.0029813732517299" LOG_EFFECT_SIZE="0.3222192947339193" MODIFIED="2017-01-07 13:03:06 +0000" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="1.5568588644477455" STUDY_ID="STD-Reuter-2006" TOTAL_1="9" TOTAL_2="6" VAR="2.4238095238095236" WEIGHT="3.0994541996986977"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.10845174638913649" CI_END="1.1758197951749398" CI_START="0.8917244815641365" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0239664531932784" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="159" I2="0.0" I2_Q="100.0" ID="CMP-002.04" LOG_CI_END="0.07034076735406536" LOG_CI_START="-0.04976930999572522" LOG_EFFECT_SIZE="0.010285728679170063" METHOD="MH" MODIFIED="2016-12-25 01:44:11 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7419137690752837" P_Q="0.0" P_Z="0.7371073878465775" Q="2.418167642870031E-33" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="251" TOTAL_2="266" WEIGHT="100.0" Z="0.33568636721819933">
<NAME>Repeat pericardiocentesis</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1789778076282174" CI_START="0.8942316857731567" EFFECT_SIZE="1.0267810440422638" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="158" LOG_CI_END="0.07150563027293885" LOG_CI_START="-0.048549945614671894" LOG_EFFECT_SIZE="0.011477842329133478" MODIFIED="2016-12-16 04:43:08 +0000" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.07052123956106769" STUDY_ID="STD-Mayosi-2014" TOTAL_1="242" TOTAL_2="260" VAR="0.004973245229229499" WEIGHT="99.21841752903688"/>
<DICH_DATA CI_END="8.729111010133504" CI_START="0.050915201322161534" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.940970016551782" LOG_CI_START="-1.2931525346631447" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2016-05-15 12:30:41 +0100" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="1.3123346456686351" STUDY_ID="STD-Reuter-2006" TOTAL_1="9" TOTAL_2="6" VAR="1.722222222222222" WEIGHT="0.7815824709631214"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.774598985924415" CI_START="0.2682422474444844" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6192468619246863" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.9900989490067624" LOG_CI_START="-0.5714728208652151" LOG_EFFECT_SIZE="0.20931306407077374" METHOD="MH" MODIFIED="2017-03-25 08:04:13 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.5992863173517804" Q="0.0" RANDOM="NO" SCALE="96.86" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="242" TOTAL_2="260" WEIGHT="100.0" Z="0.5254271049047903">
<NAME>Cancer</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.774598985924415" CI_START="0.2682422474444844" EFFECT_SIZE="1.6192468619246863" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9900989490067624" LOG_CI_START="-0.5714728208652151" LOG_EFFECT_SIZE="0.20931306407077374" MODIFIED="2017-03-25 08:04:13 +0000" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.9172749875277268" STUDY_ID="STD-Mayosi-2014" TOTAL_1="242" TOTAL_2="260" VAR="0.8413934027439914" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.093181832322129" CI_START="0.588380946072288" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8020020952159237" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.03869240550524499" LOG_CI_START="-0.23034139976104406" LOG_EFFECT_SIZE="-0.09582449712789952" METHOD="MH" MODIFIED="2017-06-27 20:55:54 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.16265413405094875" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="242" TOTAL_2="260" WEIGHT="100.0" Z="1.3962004739251892">
<NAME>Hospitalization</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.093181832322129" CI_START="0.588380946072288" EFFECT_SIZE="0.8020020952159237" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="71" LOG_CI_END="0.03869240550524499" LOG_CI_START="-0.23034139976104406" LOG_EFFECT_SIZE="-0.09582449712789952" MODIFIED="2016-12-16 08:26:51 +0000" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.15803178895223227" STUDY_ID="STD-Mayosi-2014" TOTAL_1="242" TOTAL_2="260" VAR="0.02497404631944288" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="44.40378209183373" CI_START="0.09931586437568438" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="1.6474199627195685" LOG_CI_START="-1.0029813732517299" LOG_EFFECT_SIZE="0.3222192947339193" METHOD="MH" MODIFIED="2017-05-10 14:28:00 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.6336751611520397" Q="0.0" RANDOM="NO" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="6" WEIGHT="100.0" Z="0.47656043953127375">
<NAME>Pericardiectomy</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="44.40378209183373" CI_START="0.09931586437568438" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6474199627195685" LOG_CI_START="-1.0029813732517299" LOG_EFFECT_SIZE="0.3222192947339193" MODIFIED="2016-05-14 16:11:52 +0100" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="1.5568588644477455" STUDY_ID="STD-Reuter-2006" TOTAL_1="9" TOTAL_2="6" VAR="2.4238095238095236" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.004698007871818173" CI_END="1.4754587032101028" CI_START="0.6136473923073452" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9515310744700126" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.168927058485953" LOG_CI_START="-0.2120811069750524" LOG_EFFECT_SIZE="-0.02157702424454972" METHOD="MH" MODIFIED="2016-12-25 01:49:06 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9453541753176287" P_Q="1.0" P_Z="0.8243208954595623" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="251" TOTAL_2="266" WEIGHT="100.00000000000001" Z="0.22199099256413837">
<NAME>Opportunistic infections</NAME>
<GROUP_LABEL_1>Steroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours steroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4996881654429952" CI_START="0.5992384541732421" EFFECT_SIZE="0.9479824987846378" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="34" LOG_CI_END="0.17600096431810022" LOG_CI_START="-0.22240032498251228" LOG_EFFECT_SIZE="-0.023199680332206006" MODIFIED="2016-12-16 08:30:55 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.23402288945336772" STUDY_ID="STD-Mayosi-2014" TOTAL_1="242" TOTAL_2="260" VAR="0.05476671278810316" WEIGHT="93.1781119768074"/>
<DICH_DATA CI_END="4.309711226077789" CI_START="0.23203410798131058" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.6344481710603809" LOG_CI_START="-0.6344481710603809" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-12-21 09:37:10 +0000" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.7453559924999298" STUDY_ID="STD-Reuter-2006" TOTAL_1="9" TOTAL_2="6" VAR="0.5555555555555555" WEIGHT="6.821888023192607"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2017-06-30 10:33:05 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Colchicine versus placebo in HIV-positive people</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-04-21 18:36:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Death from all causes</NAME>
<GROUP_LABEL_1>Colchicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours colchicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1216561678297197" CI_START="0.1739257172791423" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.49438506636331186" LOG_CI_START="-0.7596361969124937" LOG_EFFECT_SIZE="-0.13262556527459096" MODIFIED="2017-04-21 18:36:07 +0100" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.7366182975535748" STUDY_ID="STD-Liebenberg-2016" TOTAL_1="19" TOTAL_2="14" VAR="0.5426065162907268" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-04-21 18:38:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="19" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Constrictive pericarditis</NAME>
<GROUP_LABEL_1>Colchicine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours colchicine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.758822025617183" CI_START="0.21212786968677405" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.7603336570180594" LOG_CI_START="-0.6734022694558788" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2017-04-21 18:38:27 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.842183580318088" STUDY_ID="STD-Liebenberg-2016" TOTAL_1="19" TOTAL_2="14" VAR="0.7092731829573935" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2017-06-27 20:56:33 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>
<I>M. indicus pranii </I>versus placebo in HIV-negative people</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.031934662013215" CI_START="0.5599480136091001" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.30790973885630274" LOG_CI_START="-0.25185229165581563" LOG_EFFECT_SIZE="0.028028723600243534" METHOD="MH" MODIFIED="2017-05-10 14:27:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.844390334861896" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="95" WEIGHT="100.0" Z="0.1962808686357153">
<NAME>Deaths from all causes</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.031934662013215" CI_START="0.5599480136091001" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.30790973885630274" LOG_CI_START="-0.25185229165581563" LOG_EFFECT_SIZE="0.028028723600243534" MODIFIED="2016-12-27 08:36:32 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.3288069875895573" STUDY_ID="STD-Mayosi-2014" TOTAL_1="95" TOTAL_2="95" VAR="0.10811403508771927" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.146106669840259" CI_START="0.4372237391009701" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.7114787841368378" LOG_CI_START="-0.35929626602547543" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2017-05-10 14:27:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5191601336326528" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="95" WEIGHT="100.0" Z="0.6446405819581452">
<NAME>Deaths from pericarditis</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.146106669840259" CI_START="0.4372237391009701" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7114787841368378" LOG_CI_START="-0.35929626602547543" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2016-12-27 08:38:54 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.6289785648873253" STUDY_ID="STD-Mayosi-2014" TOTAL_1="95" TOTAL_2="95" VAR="0.3956140350877193" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.419359073345012" CI_START="0.7076627620896838" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="100.0" ID="CMP-004.03" LOG_CI_END="0.5339447092739524" LOG_CI_START="-0.15017365679612615" LOG_EFFECT_SIZE="0.19188552623891317" METHOD="MH" MODIFIED="2017-05-10 14:27:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.2715568712461357" Q="1.9081950488827903E-32" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="95" WEIGHT="100.0" Z="1.0994843560281211">
<NAME>Constrictive pericarditis</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.419359073345012" CI_START="0.7076627620896838" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.5339447092739524" LOG_CI_START="-0.15017365679612615" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2016-12-27 08:58:28 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.401854514670092" STUDY_ID="STD-Mayosi-2014" TOTAL_1="95" TOTAL_2="95" VAR="0.16148705096073515" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5156043316628154" CI_START="0.9621047768579072" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2075471698113207" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.18058583783716636" LOG_CI_START="-0.01677762907097017" LOG_EFFECT_SIZE="0.08190410438309811" METHOD="MH" MODIFIED="2017-05-10 14:26:16 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.10379325169266908" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="95" WEIGHT="100.0" Z="1.626735659762202">
<NAME>Repeat pericardiocentesis</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5156043316628152" CI_START="0.9621047768579073" EFFECT_SIZE="1.2075471698113207" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="53" LOG_CI_END="0.1805858378371663" LOG_CI_START="-0.01677762907097012" LOG_EFFECT_SIZE="0.08190410438309811" MODIFIED="2016-12-27 10:01:41 +0000" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.11593227742675685" STUDY_ID="STD-Mayosi-2014" TOTAL_1="95" TOTAL_2="95" VAR="0.013440292949354516" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="75.36597966067225" CI_START="0.12195799805683608" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.0317460317460316" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="1.8771753487897094" LOG_CI_START="-0.9137897132014177" LOG_EFFECT_SIZE="0.4816928177941458" METHOD="MH" MODIFIED="2017-01-08 15:39:57 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.4986974889381628" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="95" WEIGHT="100.0" Z="0.6765405897375162">
<NAME>Cancer</NAME>
<GROUP_LABEL_1>Corticosteroids</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours corticosteroids</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="75.36597966067218" CI_START="0.12195799805683608" EFFECT_SIZE="3.0317460317460316" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8771753487897092" LOG_CI_START="-0.9137897132014177" LOG_EFFECT_SIZE="0.4816928177941458" MODIFIED="2016-12-27 10:09:49 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="1.6394266929134582" STUDY_ID="STD-Mayosi-2014" TOTAL_1="95" TOTAL_2="95" VAR="2.687719881437159" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1273665374977466" CI_START="0.7021954769726229" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.3278423237054457" LOG_CI_START="-0.1535419722676453" LOG_EFFECT_SIZE="0.0871501757189002" METHOD="MH" MODIFIED="2017-06-27 20:56:33 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.477910843502513" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="95" WEIGHT="100.0" Z="0.7096667136184672">
<NAME>Hospitalization</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1273665374977466" CI_START="0.7021954769726229" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.3278423237054457" LOG_CI_START="-0.1535419722676453" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2016-12-27 10:36:55 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.2827675183452895" STUDY_ID="STD-Mayosi-2014" TOTAL_1="95" TOTAL_2="95" VAR="0.07995746943115363" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.9000295011132153" CI_START="0.11395925192811573" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.5910678921860432" LOG_CI_START="-0.9432504102974056" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" MODIFIED="2017-05-10 14:25:19 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.6527941821239287" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="95" WEIGHT="100.0" Z="0.44988386722991724">
<NAME>Opportunistic infections</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9000295011132144" CI_START="0.11395925192811573" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.591067892186043" LOG_CI_START="-0.9432504102974056" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2016-12-27 10:41:18 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.9012661658768656" STUDY_ID="STD-Mayosi-2014" TOTAL_1="95" TOTAL_2="95" VAR="0.8122807017543858" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2017-06-27 20:56:59 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>
<I>M. indicus pranii </I>versus placebo in HIV-positive people</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6015718966833887" CI_START="0.6866055718816678" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0486411149825785" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.20454643949188026" LOG_CI_START="-0.16329267654725746" LOG_EFFECT_SIZE="0.020626881472311377" METHOD="MH" MODIFIED="2017-05-10 14:25:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8260166466813442" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="205" TOTAL_2="209" WEIGHT="100.0" Z="0.21981319025791338">
<NAME>Deaths from all causes</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6015718966833887" CI_START="0.6866055718816678" EFFECT_SIZE="1.0486411149825785" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="35" LOG_CI_END="0.20454643949188026" LOG_CI_START="-0.16329267654725746" LOG_EFFECT_SIZE="0.020626881472311377" MODIFIED="2016-12-27 08:16:06 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.2160705175943799" STUDY_ID="STD-Mayosi-2014" TOTAL_1="205" TOTAL_2="209" VAR="0.04668646857350323" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6666919240582188" CI_START="0.15590840469658274" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5097560975609756" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.22185533105395452" LOG_CI_START="-0.8071304722713174" LOG_EFFECT_SIZE="-0.2926375706086815" METHOD="MH" MODIFIED="2017-05-10 14:24:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.26493414490737466" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="205" TOTAL_2="209" WEIGHT="100.0" Z="1.114804688388894">
<NAME>Deaths from pericarditis</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6666919240582188" CI_START="0.15590840469658274" EFFECT_SIZE="0.5097560975609756" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.22185533105395452" LOG_CI_START="-0.8071304722713174" LOG_EFFECT_SIZE="-0.2926375706086815" MODIFIED="2016-12-27 08:48:33 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.6044313544351392" STUDY_ID="STD-Mayosi-2014" TOTAL_1="205" TOTAL_2="209" VAR="0.36533726222429685" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6018384035590443" CI_START="0.33106256628384545" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7282229965156795" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.20461870152197034" LOG_CI_START="-0.480089922767847" LOG_EFFECT_SIZE="-0.13773561062293832" METHOD="MH" MODIFIED="2017-05-10 14:24:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.4303864394668563" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="205" TOTAL_2="209" WEIGHT="100.0" Z="0.7885305563066098">
<NAME>Constrictive pericarditis</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6018384035590445" CI_START="0.33106256628384545" EFFECT_SIZE="0.7282229965156795" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.2046187015219704" LOG_CI_START="-0.480089922767847" LOG_EFFECT_SIZE="-0.13773561062293832" MODIFIED="2016-12-27 08:57:42 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.40220123527019197" STUDY_ID="STD-Mayosi-2014" TOTAL_1="205" TOTAL_2="209" VAR="0.1617658336528683" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.787805277436548E-30" CI_END="1.104479318613413" CI_START="0.7976312308420236" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9385985288424312" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="126" I2="100.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.043157588114955237" LOG_CI_START="-0.09819784978564476" LOG_EFFECT_SIZE="-0.027520130835344745" METHOD="MH" MODIFIED="2017-05-10 14:23:59 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.4453675036847403" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="205" TOTAL_2="209" WEIGHT="100.0" Z="0.7631608106231467">
<NAME>Repeat pericardiocentesis</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1044793186134132" CI_START="0.7976312308420237" EFFECT_SIZE="0.9385985288424313" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="126" LOG_CI_END="0.04315758811495533" LOG_CI_START="-0.0981978497856447" LOG_EFFECT_SIZE="-0.027520130835344696" MODIFIED="2016-12-27 09:45:22 +0000" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.08303288394351502" STUDY_ID="STD-Mayosi-2014" TOTAL_1="205" TOTAL_2="209" VAR="0.006894459815977233" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-05-10 14:23:48 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="205" TOTAL_2="209" WEIGHT="0.0" Z="0.0">
<NAME>Cancer</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.35016890503706" CI_START="0.013697796074858045" EFFECT_SIZE="0.3381995133819951" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9216952603678725" LOG_CI_START="-1.8633493036118205" LOG_EFFECT_SIZE="-0.47082702162197415" MODIFIED="2016-12-27 10:24:56 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="1.6359489630746042" STUDY_ID="STD-Mayosi-2014" TOTAL_1="205" TOTAL_2="209" VAR="2.676329009784873" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="59" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-06-27 20:56:59 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="205" TOTAL_2="209" WEIGHT="0.0" Z="0.0">
<NAME>Hospitalization</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4952817781819063" CI_START="0.7999087610766936" EFFECT_SIZE="1.093658536585366" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="55" LOG_CI_END="0.17472304094028465" LOG_CI_START="-0.09695954653388453" LOG_EFFECT_SIZE="0.03888174720320008" MODIFIED="2016-12-27 10:34:44 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.15958769673282444" STUDY_ID="STD-Mayosi-2014" TOTAL_1="205" TOTAL_2="209" VAR="0.02546823294848795" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-05-10 14:22:48 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="205" TOTAL_2="209" WEIGHT="0.0" Z="0.0">
<NAME>Opportunistic infections</NAME>
<GROUP_LABEL_1>
<I>M. indicus pranii</I>
</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>M. indicus pranii</I>
</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6431545127875244" CI_START="0.6325668754298" EFFECT_SIZE="1.0195121951219512" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.21567840390728765" LOG_CI_START="-0.19889355379668822" LOG_EFFECT_SIZE="0.008392425055299711" MODIFIED="2016-12-27 10:44:29 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="0.2435216201196029" STUDY_ID="STD-Mayosi-2014" TOTAL_1="205" TOTAL_2="209" VAR="0.05930277946567619" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2017-06-30 10:33:14 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Surgical drainage versus no intervention in HIV-negative people</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.2004447732401777" CI_START="0.5212990102203788" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0710227272727273" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.3425104731134491" LOG_CI_START="-0.28291309965812544" LOG_EFFECT_SIZE="0.02979868672766185" METHOD="MH" MODIFIED="2017-04-21 18:18:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8518430446493429" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="58" WEIGHT="100.0" Z="0.18676735356804394">
<NAME>Death from all causes</NAME>
<GROUP_LABEL_1>Open drainage</GROUP_LABEL_1>
<GROUP_LABEL_2>No open drainage</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours open drainage</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no open drainage</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.200444773240178" CI_START="0.5212990102203788" EFFECT_SIZE="1.0710227272727273" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.3425104731134492" LOG_CI_START="-0.28291309965812544" LOG_EFFECT_SIZE="0.02979868672766185" MODIFIED="2017-04-21 18:18:21 +0100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.3673769025426381" STUDY_ID="STD-Strang-2004b" TOTAL_1="64" TOTAL_2="58" VAR="0.134965788521823" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9096795476536936" CI_START="0.15877181321523098" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6796875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="100.0" ID="CMP-006.02" LOG_CI_END="0.4638451613745363" LOG_CI_START="-0.799226595433036" LOG_EFFECT_SIZE="-0.16769071702924984" METHOD="MH" MODIFIED="2017-04-21 18:18:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.6027666118557132" Q="5.597952590067539E-33" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="58" WEIGHT="100.0" Z="0.5204261185441097">
<NAME>Death from pericarditis</NAME>
<GROUP_LABEL_1>Open drainage</GROUP_LABEL_1>
<GROUP_LABEL_2>No open drainage</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours open drainage</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no open drainage</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9096795476536936" CI_START="0.15877181321523098" EFFECT_SIZE="0.6796875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4638451613745363" LOG_CI_START="-0.799226595433036" LOG_EFFECT_SIZE="-0.16769071702924984" MODIFIED="2017-04-21 18:18:21 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.7419346022548001" STUDY_ID="STD-Strang-2004b" TOTAL_1="64" TOTAL_2="58" VAR="0.5504669540229884" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7629940476341865" CI_START="0.06727518591450425" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2265625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-0.11747885010502851" LOG_CI_START="-1.172145093392796" LOG_EFFECT_SIZE="-0.6448119717489122" METHOD="MH" MODIFIED="2017-04-21 18:18:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.016547833328685632" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="58" WEIGHT="100.0" Z="2.3966031898174536">
<NAME>Repeat pericardiocentesis</NAME>
<GROUP_LABEL_1>Open drainage</GROUP_LABEL_1>
<GROUP_LABEL_2>No open drainage</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours open drainage</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no open drainage</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7629940476341867" CI_START="0.06727518591450421" EFFECT_SIZE="0.2265625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.11747885010502845" LOG_CI_START="-1.1721450933927962" LOG_EFFECT_SIZE="-0.6448119717489122" MODIFIED="2017-04-21 18:18:21 +0100" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.6195161719893371" STUDY_ID="STD-Strang-2004b" TOTAL_1="64" TOTAL_2="58" VAR="0.3838002873563218" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.175557884153172" CI_START="0.13590264118166" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.54375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.3375706428729927" LOG_CI_START="-0.8667721029476052" LOG_EFFECT_SIZE="-0.2646007300373063" METHOD="MH" MODIFIED="2017-04-21 18:18:21 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.38911152661357606" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="58" WEIGHT="99.99999999999999" Z="0.8612297503444741">
<NAME>Pericardiectomy</NAME>
<GROUP_LABEL_1>Open drainage</GROUP_LABEL_1>
<GROUP_LABEL_2>No open drainage</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours open drainage</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no open drainage</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1755578841531715" CI_START="0.13590264118166" EFFECT_SIZE="0.54375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3375706428729926" LOG_CI_START="-0.8667721029476052" LOG_EFFECT_SIZE="-0.2646007300373063" MODIFIED="2017-04-21 18:18:21 +0100" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.7074368904877583" STUDY_ID="STD-Strang-2004b" TOTAL_1="64" TOTAL_2="58" VAR="0.5004669540229885" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-07-06 10:16:15 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-07-06 10:16:15 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0AAAAMVCAYAAABeIJQGAAB+fUlEQVR42uydf2Qd2f//30RVRUWp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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-07-06 09:57:54 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>&#701;Risk of bias' graph: review authors' judgements about each &#701;Risk of bias' item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-07-06 09:57:54 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>&#701;Risk of bias' summary: review authors' judgements about each &#701;Risk of bias' item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUkAAAInCAIAAACa/jxIAAAaTUlEQVR42u3dv24lxdbGYUtIiMDB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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-07-06 09:59:17 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2017-07-06 09:59:17 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-11-22 13:27:47 +0000" MODIFIED_BY="[Empty name]">Detailed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-07-06 09:59:17 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="8">
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Search set</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>CIDG SR<SUP>1</SUP> </B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>CENTRAL</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>MEDLINE<SUP>2</SUP> </B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Embase<SUP>2</SUP>
</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<B> LILACS<SUP>2</SUP>
</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>tuberculosis</P>
</TD>
<TD VALIGN="TOP">
<P>Tuberculosis [MeSH]</P>
</TD>
<TD VALIGN="TOP">
<P>Tuberculosis [MeSH]</P>
</TD>
<TD VALIGN="TOP">
<P>Tuberculosis [MeSH]</P>
</TD>
<TD VALIGN="TOP">
<P>tuberculosis</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>Pericard*</P>
</TD>
<TD VALIGN="TOP">
<P>Tuberculosis ti, ab</P>
</TD>
<TD VALIGN="TOP">
<P>Tuberculosis ti, ab</P>
</TD>
<TD VALIGN="TOP">
<P>Tuberculosis ti, ab</P>
</TD>
<TD VALIGN="TOP">
<P>Pericard*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>heart</P>
</TD>
<TD VALIGN="TOP">
<P>1 or 2</P>
</TD>
<TD VALIGN="TOP">
<P>1 or 2</P>
</TD>
<TD VALIGN="TOP">
<P>1 or 2</P>
</TD>
<TD VALIGN="TOP">
<P>heart</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>2 or 3</P>
</TD>
<TD VALIGN="TOP">
<P>heart or cardi* or pericard* ti, ab</P>
</TD>
<TD VALIGN="TOP">
<P>heart or cardi* or pericard* ti, ab</P>
</TD>
<TD VALIGN="TOP">
<P>heart or cardi* or pericard* ti, ab</P>
</TD>
<TD VALIGN="TOP">
<P>2 or 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>1 and 4</P>
</TD>
<TD VALIGN="TOP">
<P>3 and 4</P>
</TD>
<TD VALIGN="TOP">
<P>3 and 4</P>
</TD>
<TD VALIGN="TOP">
<P>3 and 4</P>
</TD>
<TD VALIGN="TOP">
<P>1 and 4</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>"Pericarditis, Tuberculous"[Mesh]</P>
</TD>
<TD VALIGN="TOP">
<P>"Pericarditis, Tuberculous"[Mesh]</P>
</TD>
<TD VALIGN="TOP">
<P>tuberculous pericarditis [Emtree]</P>
</TD>
<TD VALIGN="TOP">
<P> &#8212;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>&#8212;</P>
</TD>
<TD VALIGN="TOP">
<P>5 or 6</P>
</TD>
<TD VALIGN="TOP">
<P>5 or 6</P>
</TD>
<TD VALIGN="TOP">
<P>5 or 6</P>
</TD>
<TD VALIGN="TOP">
<P> &#8212;</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>1</SUP>Cochrane Infectious Diseases Group Specialized Register.<BR/>
<SUP>2</SUP>Search terms used in combination with the search strategy for retrieving trials developed by the Cochrane Collaboration (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_14134_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="14134">
<ADDRESS>
<DEPARTMENT>Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences</DEPARTMENT>
<ORGANISATION>Stellenbosch University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cape Town</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 trials included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="147">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 trials (10 articles) included in qualitative synthesis&lt;/p&gt;" WIDTH="184">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 trials (4 articles) included in the previous version of this review&lt;/p&gt;" WIDTH="213"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;6 articles included&lt;/p&gt;" WIDTH="118">
<FLOWCHARTBOX TEXT="&lt;p&gt;13 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="141">
<FLOWCHARTBOX TEXT="&lt;p&gt;17 records screened&lt;/p&gt;" WIDTH="135">
<FLOWCHARTBOX TEXT="&lt;p&gt;17 records after duplicates removed&lt;/p&gt;" WIDTH="132">
<FLOWCHARTBOX TEXT="&lt;p&gt;17 records identified through database searching (inception to 27 March 2017)&lt;/p&gt;" WIDTH="186"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="191"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;4 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;7 articles excluded, with reasons&lt;/p&gt;&lt;ul&gt;&lt;li&gt;4 included in previous version of the review&lt;/li&gt;&lt;li&gt;1 full-text article excluded due to ineligible study design (cross-sectional study)&lt;/li&gt;&lt;li&gt;1 study awaiting assessment (pending English translation)&lt;/li&gt;&lt;li&gt;1 ongoing study&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="221"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>